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Reported herein is a paradigm-shifting, targeted drug delivery system that leverages 
the patient’s own platelets to sense and actuate targeted delivery of a clot-augmenting 
therapeutic to a site of vascular injury. In this system, platelets target microencapsulated 
drugs through their natural aggregation behavior in the clot formation process and then 
deliver the drug by physically rupturing the microcapsule through contractile forces exerted 
during clot contraction. This cell-mediated, targeted drug delivery system utilizes 
polyelectrolyte multilayer capsules that hybridize with the patient’s own platelets upon 
intravenous administration and rupture upon platelet contraction, enabling the targeted and 
controlled “burst” release of an encapsulated biotherapeutics (Figure 1). As platelets are 
the “first responders” in the blood clot formation process, this platelet-hybridized system 
is ideal for the targeted delivery of clot augmenting biotherapeutics wherein immediate 
therapeutic efficacy is required.  
As proof-of-concept, we tailored this system to deliver the pro-clotting 
biotherapeutic, factor VIII (fVIII) for hemophilia A patients who have developed inhibitory 
anti-fVIII antibodies. The polyelectrolyte multilayer capsules physically shield the 
encapsulated fVIII from the patient’s inhibitors during circulation, preserving its 
bioactivity until it is delivered at the target site via platelet contractile force. Using an in 
vitro microfluidic vascular injury model with fVIII-inhibited blood, we demonstrate a 3.8x 
increase in induced fibrin formation using capsules loaded with fVIII at a concentration an 
order of magnitude lower than that used in systemic delivery. We further demonstrate that 
clot formation occurs 18 minutes faster when fVIII loaded capsules are used compared to 
 xiv
systemic delivery at the same concentration. Because platelets are integral in the 
pathophysiology of thrombotic disorders, cancer, and innate immunity, this paradigm-
shifting smart drug delivery system can be similarly applied to these diseases. 
 
Figure 1. Illustration of platelet-mediated “burst” delivery at a site undergoing 
bleeding. Polyelectrolyte multilayer microcapsules loaded with a clot-promoting drug 
(i.e. factor VIII (fVIII)) are intravenously administered to the patient. The patient’s 
own platelets hybridize with the microcapsule and target it to the injury site through 
their natural clotting behavior. Once platelets begin to contact within the clot 
structure, the physical force ruptures the microcapsule and delivers the full 




CHAPTER 1. INTRODUCTION 
Intravenous administration of a “free” drug results immediate exposure of the drug 
to the vascular system (systemic exposure). While this may be desirable in treating certain 
conditions (i.e. acetaminophen for general muscle soreness), this can lead to off-target 
interactions between the administered drug and healthy environments, which can lead to 
life threatening complications for certain drugs. The rise of nanotechnology in recent 
decades has had substantial impact on the fields of chemistry, biomedical engineering, and 
medicine as a vast array of nanoparticles have been developed that enable targeted delivery 
of therapeutics that have traditionally been administered systemically. Nanoparticle-based 
targeted delivery has been shown to increase efficacy by altering biodistribution, increasing 
drug half-life and solubility, and lowering potential risk of side effects. 2-8 Commonly 
developed drug carrying nanoparticles, in particular ones that have achieved FDA 
approval, have relied upon delivery mechanisms that operate over extended time scales 
(i.e. diffusion or site-specific biodegradation).9 While this has been shown to increase 
efficacy and decrease the side effect profile for several drugs (i.e. Doxil® - liposomal 
doxorubicin in treating malignant tumors),10 several life-threatening disorders require 
immediate exposure of the full dose of the treatment at the diseased site, rendering these 
nanoparticle-based targeted delivery technologies insufficient. 
 Motivation 
Hemostasis is an extremely sensitive system that exists on a continuum.  Pathologic 
coagulation that requires therapeutic intervention occurs on both ends of the continuum 
(i.e. deep vein thrombosis or hemorrhage). The current clinically-used treatment standard 
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requires systemic administration of the appropriate treatment (small molecule, recombinant 
biologic, or plasma products) to break-up occlusive clotting or promote clotting for non-
compressible hemorrhage.11-14 These treatments can drive the hemostatic response to the 
other end of the continuum due to their off-target effects (i.e. causing hemorrhagic stroke 
when treating thrombosis or causing thrombosis when treating bleeds).15,16 Additional 
drawbacks to these treatment options include restricted administration timeframes for 
thrombolytics (due to their off-target side effects), immediate access to large donor pools, 
storage of both frozen and freshly thawed plasma products, and adverse 
immunomodulatory responses for antihemorrhagics.15,17,18 
As both platelets and red blood cells are involved in the clot formation process and 
are major constituents of blood clots, significant research has been conducted into cell-
mediated strategies for targeted delivery of clot augmenting therapies.19-21 However, the 
previously developed strategies have focused on delivery of fibrinolytics and, more 
importantly, do not enable an immediate “burst” release of the incorporated therapeutic. 
An advantageous feature of innate platelet behavior is their ability to physically contract 
on an underlying substrate after site-specific activation, as in the context of a clotting 
environment, which has yet to be used to perform targeted drug delivery. This work 
capitalizes upon this behavior to effect drug targeting (via platelet adhesion to sites of 
clotting) and drug delivery (via platelet contraction after activation).  
Specifically, fibrinogen coated polyelectrolyte multilayer microcapsules (PEM 
capsules) that are loaded with a hemostatic drug (i.e. fVIII to treat bleeds in hemophilia A 
patients) are intravenously administered, after which the patient’s own platelets adhere to 
the surface fibrinogen, forming a platelet hybridized PEM capsule (platelet-HyPEM) 
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(Figure 2A).1 These structures circulate quiescently through healthy vascular environments 
(Figure 2B), but once exposed to a site undergoing active bleeding, the hybridized platelets 
activate and adhere the PEM capsule to the injury site (Figure 2C). Once the platelets begin 
to contract, the contractile force generated in the forming clot physically ruptures the PEM 
capsule wall, providing a “burst” release of the targeted drug for immediate exposure 
(Figure 2D). Utilizing the biomechanical behavior of the patient’s own platelets is a 
previously unreported drug delivery paradigm, which could drastically advance future 
“smart” targeted drug delivery strategies in the context of hematological disorders. 
 
Figure 2. Illustration of “smart” drug delivery paradigm leveraging the patient’s own 
platelets for targeted delivery and controlled release. (A) Polyelectrolyte multilayer 
(PEM) capsules loaded with a biotherapeutic payload are intravenously administered 
to the patient whereupon the patient's own platelets adhere to the PEM capsule via 
surface fibrinogen (green) during circulation to form a platelet-hybridized 
microcapsule (plt-HyPEM). (B) The patient's platelets that comprise the hybrid 
microcapsule remain quiescent during circulation. Only when the hybrid 
microcapsules enter an area undergoing active clotting (C), do the hybridized 
platelets activate upon exposure to thrombin and target the platelet-HyPEM to the 
site of injury by adhering to exposed collagen at the site of vascular injury and/or 
integrating into the forming fibrin network of the nascent clot. (D) Finally, the 
physical force exerted by platelet-mediated contraction within the platelet-HyPEM 
and nearby platelets physically ruptures the platelet-HyPEM capsule, enabling 
delivery of a high dose of the encapsulated biotherapeutic (purple) to the target site. 
 Research Objectives and Specific Aims 
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The long-term goal of this project is to develop a technology for the targeted delivery 
of factor VIII (fVIII) to abate bleeds in hemophilia A patients with inhibitory antibodies. 
The overall objective of this thesis was to develop a targeted drug delivery paradigm that 
leverages platelet biomechanical behavior (specifically site-specific aggregation and 
contraction) for both targeting and delivery. The central hypothesis of this work is that 
platelets will adhere onto a fibrinogen coated spherical surface (the drug loaded vehicle), 
and that their contraction (once activated) in a clotting environment is sufficient enough to 
mechanically disrupt a drug-carrying microparticle such that rupture of the particle and 
release of the drug is achieved. This hypothesis is substantiated upon the significant 
research conducted regarding platelet adhesion onto fibrinogen coated surfaces and their 
contractile behavior on underlying substrates that has been measured on the bulk and 
single-cell length scales. 
1.2.1 Specific Aim 1: Feasibility of a Platelet-Mediated Targeted Drug Delivery 
Mechanism  
The viability of a platelet-mediated drug delivery system depends on the realization 
of several factors, including: platelet adhesion onto microparticles to form platelet-
hybridized microparticles, adhesion of the hybrid microparticles to sites of vascular injury, 
and the ability of the microparticle to rupture due to platelet contractile forces. Emulsion 
microparticles were originally investigated as the drug delivery microparticle due to their 
ease of fabrication and current use in several pharmaceutical formulations.22  
In this aim, I investigated two emulsification methods for fibrinogen stabilized 
emulsions, and their effects on emulsion size and stability. I then developed a microfluidic 
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experimental assay to demonstrate two factors that are crucial to the proposed platelet-
mediated targeted drug delivery paradigm. I show that not only can emulsion droplets 
adhere to “micro-thrombi”, but also that circulating single platelets can adhere to the 
fibrinogen coated emulsion surface. Furthermore, I show in the developed microfluidic 
assay that their contractile force under ADP or thrombin activation is sufficient enough to 
morphologically disrupt the emulsion droplets and rupture the fibrinogen coating on the 
droplet surface, thereby proving the feasibility of this platelet-mediated paradigm. 
1.2.2 Specific Aim 2: Modification of Polyelectrolyte Multilayer Microcapsules to 
Enable Platelet Contractile Force Mediated Rupture 
Polyelectrolyte multilayer (PEM) capsules are well-established self-assemblies that 
have been heavily investigated as possible drug delivery microcapsules.23,24 They are easily 
fabricated via layer-by-layer deposition of polyelectrolyte polymers onto a sacrificial 
templating core particle followed by core removal, enabling facile control over the 
mechanical properties by adjusting polyelectrolyte shell thickness.25,26 Of particular 
consequence to a drug delivery paradigm based upon contractile forces is that their 
structural integrity has been shown to be susceptible to mechanical force generating events 
on the cellular level, such as cellular uptake.27 As such, their suitability to function as drug-
encapsulating microcapsules that are susceptible to platelet contraction-mediated drug 
release was explored. In this aim, I detail modifications to PEM capsules that were made 
in order to facilitate the desired interactions with platelets, specifically their ability to form 
hybrid complexes (platelet-HyPEMs) with quiescent platelets and rupture via contraction 
of activated platelets. 
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1.2.3 Specific Aim 3: Platelet-Mediated Targeted Delivery of Factor VIII In Vitro 
Hemophilia A is a genetic bleeding disorder wherein patients cannot produce 
functional factor VIII, a pro-coagulant plasma protein. They therefore must receive 
prophylactic or on-demand injections of fVIII to prevent and abate bleeding events.28,29 
Approximately 30% of severe hemophilia patients produce an inhibitory antibody to fVIII, 
which renders replacement therapy ineffective due to its systemic administration.30 These 
patients must then use alternative pro-clotting factors that are associated with higher risks 
of thrombotic side effects or have shorter half-lives.31-34 Platelet-HyPEMs were 
investigated as fVIII delivery microcapsules that circumvent interaction between the 
patient’s inhibitors and administered fVIII as an alternative therapy with the potential of 
lower side effects.  
This chapter focuses on evaluation of the in vitro hemostatic efficacy of fVIII 
loaded platelet-HyPEMs using healthy and fVIII inhibited blood samples. A microfluidic 
vascular injury model was used to determine effects on fibrin formation in a clotting 
environment. Results show that fVIII-loaded HyPEMs enable more fibrin formation 
compared to “free” fVIII in fVIII-inhibited blood. In addition, a clot duration assay was 
used to investigate clot formation on the bulk scale, which shows that fVIII-loaded 
HyPEMs decrease clot formation time to that of a healthy patient compared to a fVIII-
inhibited control and “free” fVIII. 
 Significance 
This work has significance in two areas – the development of a paradigm-shifting 
mechanism within the targeted drug delivery field and its application to potentially 
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circumvent inhibitor interference in hemophilia A patients. Leveraging the naturally 
occurring and site-specific biomechanical behavior of the patient’s own platelets, 
specifically their contraction after activation, to effect targeted drug delivery is a paradigm-
shifting approach, with potential to not only deliver hemostatic-regulating drugs, but also 
chemotherapeutics and immunomodulatory therapies as platelets are involved in these 
biological systems as well. However, within the context of clot-augmenting drugs, this 
technology has immense impact as these pathologies are often immediately life threatening 
if left untreated. This targeted drug delivery method enables delivery of larger therapeutic 
dose to the target site compared to what is allowed when administering a formulation that 
results in systemic exposure. As such, this can be a very powerful technology in delivery 
biotherapeutics to quickly abate active bleeds due to non-compressible injuries or for 
patients who are at a high risk of hemorrhage. 
For severe hemophilia A patients, prophylactic treatment with replacement factor is 
recommended in order to prevent spontaneous bleeding episodes; however, this treatment 
regimen is extremely costly, as it requires multiple infusions per week. In 2015, the 20,000 
hemophilia A patients in the United States spent approximately $9.3 Billion dollars on 
drugs to prevent or abate bleeding episodes.35 The subset of patients that develop inhibitors 
to fVIII replacement therapy are left with few treatment options to prevent or abate 
bleeding and spend an average of $978,955 per year on treatment costs.35,36  
 Clearly, an unmet medical need exists for an effective, yet safe, treatment for 
hemophilia A patients with inhibitors. Encapsulating fVIII in a polymer microcapsule 
affords “shielding” from the patient’s inhibitors during circulation, preserving its 
bioactivity for when it is released on the injured site. Furthermore, imparting targeting and 
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“burst” delivery capabilities into the microcapsule can enhance fVIII efficacy while 
decreasing the risk of thrombotic side effects. Such a treatment system will drastically 
improve the lives of hemophilia patients with inhibitors, as they will be able to quickly and 
effectively treat bleeding episodes.  
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CHAPTER 2. BACKGROUND AND LITERATURE REVIEW 
 Targeted Drug Delivery 
Nanoparticle-based targeted drug delivery systems offer many advantages for 
intravenous therapies in comparison to administration of the “free” drug (i.e. increased 
solubility, alteration of biodistribution and pharmacokinetics, and longer drug half-life).8 
Most notable is the advantage of targeting the therapy strictly to the diseased site. 
Theoretically, the increased drug accumulation at the diseased area can increase the 
efficacy of a drug while using a lower dose compared to the “free” drug that is targeted 
systemically. Targeting also decreases the drug’s off-target interactions with healthy 
tissues, thereby lowering the potential risk of side effects. 
A substantial amount of research has been conducted into targeted drug delivery 
systems for a wide range of diseases, and as such, a vast array of targeted delivery 
mechanisms have been developed. Generally, these can be classified into passive or active 
targeting.37,38 Passive targeting mechanisms do not include a feature in the nanoparticle 
that can specifically target the diseased site and instead rely on a feature of the diseased 
site or physical characteristic of the nanoparticle for accumulation.37 Utilization of the 
enhanced permeability and retention (EPR) effect for tumor-targeting formulations is a 
classic example of a passive targeting mechanism.37,39,40 Targeted drug delivery systems 
that employ active targeting display a targeting moiety on the nanoparticle. Targeting 
features include biochemical moieties like peptides or antibodies specific to a receptor that 
is upregulated or present in a diseased state,41-43 magnetic nanoparticles that guide the drug 
delivery construct to the desired site by application of an external magnet,44,45 or cell-
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mediated strategies wherein nanoparticle constructs are hybridized (covalently or non-
covalently) with disease regulating cells to “hitch-hike” to the target site.46 
In addition to active or passive targeting, incorporating a stimuli responsive delivery 
mechanism offers additional control by enabling site-specific release of the therapeutic.47,48 
This can be accomplished by incorporating features subject to intrinsically present or 
externally applied stimuli. Popular intrinsic stimuli include increased redox 
environments,49 lower localized pH environments,41 or sensitivity to specific enzymes.50 
Utilization of heat,44 lasers,51,52 or ultrasound53-55 are external methods that have been 
extensively developed in the literature as well.  
Ruan et al. leveraged the EPR effect and several intrinsic aspects of the tumor 
environment for targeted delivery of doxorubicin from a multi-particle construct.56 
Investigators synthesized gelatin nanoparticles to which they covalently coupled (via 
EDC/NHS chemistry) gold nanoparticles that were decorated with PEG and doxorubicin 
with a hydrazone crosslinker. The particle composites were targeted to tumors through the 
EPR effect, and once there, underwent gelatin degradation via matrix metalloprotease-2, 
which is over expressed in tumor sites. Gelatin degradation frees the smaller gold 
nanoparticle constructs, enabling further interrogation of the tumor mass. Doxorubicin is 
then released in the acidic environment within the tumor or after cellular uptake in the 
lysosome via the pH sensitive hydrazone bond. Utilizing an in vivo model of B16F10 tumor 
bearing mice, they were able to show minimal changes in tumor growth determine via 
volume volume over 22 days, which was statistically significant compared to free 
doxorubicin and the controls.  
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Utilization of the EPR effect for nanoparticle tumor targeting suffers from two major 
drawbacks: (1) nanoparticles typically undergo rapid clearance, which can only be 
extended by a certain extent using surface functionalization strategies (i.e. PEGylation), 
and (2) access to the full tumor tissue is severely limited due to interstitial pressure and 
heterogeneous vascularization.37,40,57 To address these shortcomings, a cell-mediated 
strategy was developed that targets circulating monocytes after intravenous 
administration.58 When these monocytes differentiate into macrophages in tumor 
environments, they can exhibit substantial extravasation, entering areas that are 
inaccessible when relying on the EPR effect alone.59 This paradigm utilizes flat-disk 
shaped “backpack” particles (to circumvent cellular uptake) comprised of several layers 
fabricated from layer-by-layer assembly with a structural layer consisting of 
poly(allylamine hydrochloride) and iron oxide magnetic nanoparticles and a ligand 
displaying layer consisting of poly(acrylic acid) and poly(allylamine hydrochloride) 
functionalized with biotin. Streptavidin is then deposited on the biotin layer, followed by a 
biotinylated antibody of choice, enabling “hitchhiking” of monocytes. Investigators 
showed significant accumulation of hitchhiked backpack particles compared to free 
particles in inflamed tissue compared to other organs (except the heart). They then showed 
in a lung inflammation model, backpacks hitchhiked to monocytes significantly 
accumulated more in the lungs compared to other organs, which was not seen in healthy 
mice. 
Hyaluranic acid (HA) polymeric micelles are commonly used nanoparticle 
constructs in chemotherapeutic delivery as HA naturally targets CD44, which has been 
shown to be overexpressed in several tumor cell lines.60 Polymeric micellular constructs 
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have been shown to be unstable after intravenous administration, however, which results 
in premature and off-target drug release.61 To combat this undesirable behavior, Han et al. 
fabricated HA polymeric micelles with redox-sensitive crosslinked cores to enhance 
stability in complex suspensions like whole blood.62 This was achieved by covalently 
attaching a disulfide displaying polymer to the HA polymer, which after micelle formation 
and doxorubicin loading, was crosslinked via a redox reaction with dithiothreitol. Disulfide 
crosslinking of the particles imparts redox sensitive release to leverage the substantial 
higher glutathione concentration in the intracellular environment of tumor cells. In vivo 
determination using SCC7 tumor-bearing mice demonstrated significantly increased 
nanoparticle accumulation in tumor tissue for core crosslinked particles compared to 
uncrosslinked particles, which was further supported by decreased doxorubicin 
concentration in plasma but increased concentration in the tumor tissue. Investigators 
further showed a significant decrease in tumor volume and weight when core crosslinked 
particles were used compared to uncrosslinked core particles or free doxorubicin. 
A disease target that has proven to be extremely difficult to target are circulating 
tumor cells (CTCs). Gao et al. reported a doxorubicin-loaded nanomissle constructed from 
a mesoporous silica nanoparticle displaying two nuclei acid aptamers to target the epithelial 
cell adhesion molecule (EpCAM) and CD44 on colorectal CTCs.63 Mesoporous silica 
nanoparticles were chosen because of their easily adjusted porosity to tune drug loading 
and release, as well as facile surface modification to incorporate the aptamers for active 
targeting. The investigators demonstrated an 8-hour stability in blood and ability of the 
nanomissles to bind to CTCs in whole blood. In vitro, the developed nanomissle 
significantly downregulated SW620 (murine colorectal carcinoma cell line) adhesion to 
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human umbilical vein endothelial cells as well as their proliferation, suggesting a decreased 
ability to metastasize. Most impressively, it was then demonstrated in an in vivo model of 
colon carcinoma metastasis to the lungs that tumor metastasis was decreased from 
approximately 70 pulmonary sites when free doxorubicin was used compared to almost 
zero when the nanomissles were used. 
A recent example of a multi-functional targeted drug delivery particle for 
photochemotherapy has been reported that utilizes both antibody targeting and near IR 
delivery enhancement.51 Here, Lee and co-workers fabricated polyethyleneimine-coated 
double nano-emulsions that were loaded with doxorubicin and indocyanine green as a 
photosensitizer. The nano-emulsions displayed anti-HER2 antibodies on the surface to 
target HER2 positive breast cancer cells. The researchers demonstrated in vitro a 
significant decrease in viability of MDA-MB-453 cells from approximately 80% to less 
than 20% when samples were preoxygenated and exposed to near IR laser treatment, 
enhancing cellular uptake of doxorubicin via photothermal and photodynamic 
mechanisms. 
Clearly, a vast array of nanoparticle-based targeted drug delivery strategies have 
been developed, particularly in the field of chemotherapeutic delivery. Methodologies to 
impart targeting or delivery can be chosen from the toolbox of thoroughly investigated 
mechanism and stimuli and then tailored to specific cells or diseased sites, but little has 
been done in developing new mechanisms for targeting and delivery. This is problematic 
for conditions requiring immediate targeting and release of the drug, as few systems have 
been developed that result in immediate drug release at a target site without the need of an 
applied external stimuli. In treating thrombosis or severe bleeds, a targeted drug delivery 
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mechanism that can be efficacious immediately after administration would be extremely 
appealing, as treatment time is critical for these conditions. 
 Targeted Drug Delivery for Clot-Augmenting Therapies 
Hemostasis is a complex system that exists on a continuum between pathologic 
bleeding (hemorrhage) and clotting (thrombosis). It involves platelets, red blood cells, and 
several plasma proteins and zymogens that function as cofactors and enzymes once 
activated. Due to the integral and complex nature of both platelet function (Appendix A) 
within clot formation and the coagulation cascade (Appendix B), genetic mutations 
(affecting coagulation proteins or platelet function), severe injury, or cardiovascular 
disease can have devastating effects that can result in life-threatening bleeding or clotting 
disorders (Appendix C).  
2.2.1 Hemostasis Overview 
Platelets are anucleate cell fragments of megakaryocytes with a diameter of 3.5 m 
that are involved in several biological processes, but are integral in the clot formation 
process.64 During primary hemostasis, circulating platelets adhere to sites of vascular injury 
through newly exposed matrix proteins. This adhesion event activates the platelet, resulting 
in further recruitment of circulating platelets, aggregation, and formation of a platelet-plug 
to initially stem bleeding.  
During the formation of the platelet-plug, the coagulation cascade occurs wherein 
plasma zymogens and proteins operate in positive or negative feedback loops to promote 
coagulation or anticoagulation to achieve and maintain hemostasis. The main result of the 
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coagulation cascade is production of the enzyme thrombin, which cleaves fibrinogen into 
fibrin, enabling its self-assembly and polymerization. The fibrin network enhances the 
structural integrity of the clot to further stem bleeding. 
Late-stage platelet recruitment and activation occurs when circulating platelets 
adhere to this fibrin network. Once activated, platelets exert a contractile force on this 
network, resulting in substantial clot contraction. This increases the stiffness of the clot to 
further increase its structural integrity as well as brings the injured vascular walls closer 
together to facilitate healing at later stages. Platelet contraction has been studied both on 
the bulk scale within the context of whole blood and platelet rich plasma clots and on the 
single-cell level.64 Initial studies focused on bulk scale investigations measured the tension 
within a contracting clot, demonstrating a maximum contractile tension generated at ~15 
minutes after calcium-induced activation.65 Contraction of a whole blood clot results in a 
loss of roughly 80% of serum from within the clot, which decreases the clot to about 1/3 
of its original size.66,67  
Interestingly, single-cell studies have elucidated that the extent of platelet 
activation and the generated contractile force is highly variable between platelets even from 
the same patient sample, and can be heavily influenced by the stiffness of the substrate as 
well as the concentration of soluble clotting factors (i.e. thrombin). Average contractile 
forces of individual platelets measured via atomic force microscopy was determined to be 
20 nN; however, the magnitude ranged from 1.5 to 79 nN per platelet.68 To further 
investigate this large distribution in platelet biomechanical behavior, Qiu et al. elucidated 
the mechanosensing ability of platelets, demonstrating that platelet adhesion, spreading, 
and subsequent activation increased with increasing stiffness of the fibrinogen-coated 
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substrate to which the platelets were adhered.69 This large range in platelet contraction was 
again demonstrated using a platelet-contraction cytometer and further showed that platelet 
contraction reached a maximum when the platelets were adhered onto a substrate 
exhibiting a stiffness of 75 kPa and exposed to 5 U/mL of thrombin.67 
2.2.2 Targeted Drug Delivery Strategies 
While systemic administration of pro-coagulants (plasma products or clotting 
factors) or thrombolytics and fibrinolytics remains the clinical standard to abate 
uncontrolled bleeding or treat thrombosis, respectively, there exist several drawbacks to 
currently used therapies including the need of large donor pools, storage of both frozen and 
freshly thawed plasma products, immunomodulatory response, bloodbourne disease, 
restricted administration time frames, and thrombotic or hemorrhagic side effects.12,13,16-
18,70,71 Targeted drug delivery systems have become a major focus of research in recent 
years because they have demonstrated a potential to lower the risk of side effects and 
increase efficacy for intravenously administered small molecule or biologic therapies by 
overcoming poor drug solubility, off target interactions with healthy tissues, altering 
pharmacokinetic profiles, and enabling longer half-lives. 2-8 As such, there have been 
several advances in the literature developing synthetic technologies to regulate the clotting 
process, thereby removing the need of human-derived products and decreasing the 
possibility of adverse side effects. Interestingly, several of these nanoparticle constructs 
act as the therapeutic itself and do not contain a “traditional” drug. 
Several synthetic platelet strategies have been developed to stem bleeding that 
utilize nanoparticles decorated with ligands specific to clotting proteins or activated 
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platelets, thereby mimicking platelet adhesion and aggregation.72-77 Shoffstall et al. 
developed polymeric nanoparticles fabricated from block copolymers, PLGA-b-PLL-b-
PEG, decorated with the peptide GRGDS, which binds to platelet GPIIb/IIIa in order to 
increase platelet aggregation after a blunt trauma.75 The investigators used a murine liver 
trauma model to demonstrate an increase in 1 hour survival using a scrambled peptide 
control from 45% to 92% with their optimized construct. SynthoPlateTM, a liposomal 
nanoparticle, has been iteratively developed to display three targeting peptides specific for 
vWF (that is noncompetitive with the platelet binding domain), collagen, and a fibrinogen 
mimetic that binds to GPIIb/IIIa.72-74 These nanoparticles bind to injury sites and platelets 
to increase adhesion and aggregation, contributing to enhanced primary and secondary 
hemostasis. To better recapitulate the physical properties of platelets, Anselmo et al. 
developed a flexible, discoid-shaped nanoparticle from layer-by-layer deposition of 
poly(allylamine hydrochloride) and bovine serum albumin onto a removable polystyrene 
core, which displayed the same targeting ligands as SynthoPlateTM.78 Their technology 
resulted in a 65% reduction in bleeding time compared to the control using a murine tail 
transection model. Brown et al. decorated ultra-low crosslinked poly(N-
isopropylacrylamide-co-acrylic acid) microgels79 with variable domain-like recognition 
motif specific to fibrin, H6, to create platelet-like particles.77 The investigators showed in 
a rat femoral vein injury model that injection of these particles decreased bleeding time to 
a regime similar to what is seen with fVIIa, proposing a therapy with similar efficacy but 
with the potential of a lower risk of thrombotic side effects.  
While targeted therapeutics to abate bleeding has heavily relied on specific ligand 
interactions to effect targeting, delivery of fibrinolytics to treat thrombosis spans a much 
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larger scope in the targeting technologies that have been developed. Ultrasound has been 
used both by Tiukinhoy-Laing et al. and Kawata et al. to deliver tissue plasminogen 
activator (tPA) from liposomes and gelatin constructs, respectively.53,54 Voros et al. 
developed a magnetically targetable nanoparticle by encapsulating an iron oxide nanocube 
core with deposited BSA and tPA.80 Magnetics were used to direct the construct and 
resulted in increased dissolution and at a faster rate using in vitro models.  
Absar and co-workers utilized the c-terminal gamma chain of fibrinogen to target 
“camouflaged” tPA and liposomal tPA to clots.81,82 While liposomal tPA utilized diffusion 
for delivery, “camouflaged” tPA exploited a thrombin-cleavable linker that protected tPA 
during circulation, but enabled full exposure of the enzyme in sites undergoing clotting. 
While the camouflaged construct resulted in lower efficacy than free tPA in vitro, the 
liposomal tPA resulted in decreased clot weight compared to free tPA in vivo.  
The enhanced shear rate present in stenotic vascular environments was utilized by 
Korin et al. to effect targeted delivery of tPA.83 PLGA nanoparticles fabricated from spray 
drying aggregate into microparticles due to their hydrophobic properties; however, these 
aggregates break apart in environments of high shear, like those experience in thrombotic 
environments (100 dyne/cm2). These were decorated with tPA using biotin-streptavidin 
and were demonstrated to greatly enhance in vivo survival using a murine pulmonary 
embolism model, wherein all control mice died within 1 hour but >80% of the experimental 
cohort survived. 
As erythrocytes and platelets are major components of blood clots, these blood cell 
populations are advantageously poised for targeted delivery of hemostatic or thrombolytic 
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drugs. Indeed, several innovative technologies have been developed using erythrocytes or 
platelets to deliver clot-augmenting therapeutics via cell surface display. For example, 
Murciano et al. conjugated tPA onto erythrocytes and showed a significant enhancement 
in circulation time and bioactivity of tPA-erythrocyte conjugates upon reinjection in 
comparison to free tPA.19 Building upon this system, Zaitsev et al. coupled a complement 
receptor type-1 antibody to tPA, which allowed the tPA mutant to bind to erythrocytes 
upon injection, similarly showing enhancements of bioactivity, circulation time, and clot 
lysis without the need to harvest and re-inject cells.20 Chen et al. developed a 
staphylokinase (a thrombolytic) mutant containing a RGD motif that enabled platelet 
binding and resulted in a decrease in clot lysis time compared to free staphylokinase.84 A 
cell-nanoparticle construct was reported on by Chen et al. wherein heparin-poly-L-lysine 
nanoparticles adhered to red blood cells through electrostatic interactions.85 While they 
detached in environments of high shear rates, the investigators showed a higher level of 
anti-fXa activity, which lasted for 100 hours in vivo compared to 20 hours for free heparin. 
This is likely due to the ability of nanoparticles adhered onto the red blood cells to avoid 
clearance systems.  
Absar et al. attached tPA to platelets through a RGD motif, which binds to 
GPIIb/IIIa.86 The RGD motif in their construct was linked to tPA through a heparin 
cleavable linker, thereby facilitating release of tPA when the platelets were in a thrombotic 
environment. Investigators showed an increase in clot lytic activity and a decrease in clot 
weight compared to free tPA.  
Clearly, previously reported technologies that augment clotting span an extensive 
scope in the targeting and delivery methods that have been employed, including: ligand 
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specific peptides for targeting and adhesion, enzyme cleavable linkers, magnetic targeting 
or ultrasound-mediated release, enhanced shear rates, red blood cells, and platelets. An 
interesting behavior within the clotting process that has yet to be capitalized upon, 
however, is platelet’s ability to exert a substantial contractile force during clot formation 
that results in a remarkable extent of clot contraction. The development of this drug 
delivery mechanism is herein described, which leverages the patient’s own platelets to 
target drug encapsulating microcapsules to sites undergoing active bleeding and deliver the 
drug through contraction on the microcapsule, resulting in rupture and drug release. 
Utilizing the natural behavior of the patient’s own cells as the sensor and actuator of 
targeted drug delivery is an empowering, elegant, and paradigm-shifting mechanism within 
the field. 
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CHAPTER 3.  FEASIBILITY OF A PLATELET-MEDIATED 
TARGETED DRUG DELIVERY MECHANISM 
 Introduction 
In order to conduct initial investigations into the feasibility of a platelet-mediated 
drug delivery system, a model drug delivery particle was required that: (1) was an 
established particle in the field of drug delivery, (2) could display fibrinogen on the surface 
of the particle to enable platelet adhesion and clot targeting, and (3) could be easily 
fabricated from well-established methods. As such, emulsion particles were initially used 
as the model drug delivery vehicle as they are an established particle for pharmaceutical 
and cosmetic formulations, 87-91  can use fibrinogen as the oil/water interface stabilizer, and 
can be easily fabricated from a variety of methods. Furthermore, due to the tunability of 
droplet stability via surfactant combinations, emulsification method, and suspension 
properties, we believed this would provide access to a variety of particles exhibiting 
different mechanical properties to thoroughly investigate a contractile-force mediated 
delivery mechanism. 
3.1.1 Emulsions 
Emulsions are nano- or micron-sized liquid droplet particles suspended in an 
insoluble liquid phase. An emulsion is formed when sufficient energy is introduced into a 
system of two insoluble liquids and surfactant (and in some cases, an additional co-
surfactant). Common surfactants and co-surfactants include: synthetic compounds (i.e. 
Span 20 or Tween 85),92 nanoparticles (i.e. microgels or carbon nanotubes),93,94 and 
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proteins (i.e. bovine serum albumin (BSA) or -lactoglobulin).95 The imparted energy 
brings the interfacial tension between the two phases to a sufficiently low level, which is 
further stabilized by the surfactant, creating a fluid-like interface. While all emulsions are 
kinetically stable initially after formation, nano-sized emulsions are additionally 
thermodynamically stable under certain conditions.96,97 This makes them attractive 
formulation technologies for various fields (i.e. food sciences, cosmetics, and 
pharmaceutical sciences). The simplest, and by far, most common emulsion form is an oil-
in-water (o/w) emulsion; however, various other architectures such as water-in-oil 
emulsions and water-in-oil-in-water double emulsions51,96 have been developed for various 
applications.  
3.1.2 Emulsions in Drug Delivery Systems 
Due to their ease of fabrication from FDA approved compounds and facile 
manufacturing scale-up, emulsions have been heavily utilized in the field of 
pharmaceutical science for drug formulations. Their chemical composition and size are 
easily tunable, making them applicable for a variety of administration profiles including 
transdermal, subcutaneous, oral, and parenteral.87-90  
Of particular pertinence to clot augmenting biotherapeutics are parenteral 
formulation strategies, as they are currently delivered intravenously to decrease the time 
for onset of action and maintain bioactivity. Substantial research has been conducted on 
nano-emulsions for intravenous delivery of a variety of lipophilic drugs. Indeed, the degree 
of lipophilicity of the encapsulated drug has been shown to affect the rate of diffusion out 
of the nano-emulsion.98 Various investigations have shown this lipophilicity-mediated 
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controlled diffusive release via nano-emulsion encapsulation improves the circulation 
times for a variety of chemotherapeutics.99-102 Ganta et al. encapsulated chlorambucil in a 
soybean oil emulsion using egg phosphatidylcholine and cholesterol as the surfactant 
mixture.99 Not only was there a significant improvement in pharmacokinetics compared to 
the free drug when injected intravenously into C57 BL/6 mice, the growth rate of colon-38 
adenocarcinoma was significantly suppressed. Zhang et al. modified the hydrophobic 
properties of doxorubicin by forming an oleic acid ionic complex to enhance encapsulation 
from 30% (unmodified doxorubicin) to 93%.102 Not only were pharmacokinetics in mice 
similarly improved compared to the free doxorubicin, the concentration of doxorubicin 
found in the heart, lungs, and kidneys were lower. 
Several strategies have been employed to modify the chemical and physical 
properties of the droplet surface to further enhance circulation or rapidly target them to 
diseased sites in order to avoid clearance by the liver or phagocytosis. PEGylation is by far 
the most widely employed method to enhance circulation time due to its non-fouling 
properties, imparting the structure it coats with a “stealth”-like property.103,104 Alayoubi et 
al. conducted an interesting investigation wherein nano-emulsions (loaded with vitamin E 
as an anticancer agent against mammary adenocarcinoma cells) were either coated with 
poloxamer or PEG.105 Poloxamer coated nano-emulsions showed increased plasma protein 
adsorption and a circulation half-life of 1.7 hours. Nano-emulsions coated with PEG 
demonstrated a substantially longer half-life of 12.3 hours. The authors attribute this 
increase in circulation time to the brush-like architecture of PEG on the droplet surface that 
enhances the steric repulsion of plasma protein adsorption onto the surface, thereby 
decreasing cellular uptake. Nano-emulsion targeting has been achieved through inclusion 
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of peptide targeting moieties onto the surface. Most notably by including an RGD peptide 
sequence onto the surface to target emulsions to tumors.106 
Due to the substantial list of benefits seen in parenteral emulsion delivery of drugs, 
it is not surprising that several drugs are commercially available that use nano-emulsion 
formulations, including: Cleviprex (clevidipine), Diazemuls (Diazepam), and Diprivan 
(propofol). Due to their established use in the field, ease of manufacturing over various 
methodologies, and facile tunability, we believe emulsions to be a pragmatic particle with 
which to conduct initial investigations into the feasibility of platelet-mediated drug 
delivery. As platelet contractile force-induced particle rupture is the mechanism that results 
in drug delivery in our proposed paradigm, it was essential that the emulsions demonstrated 
a fine-tuned stability: stabile enough to remain intact during storage and circulation, yet 
still allow for contractile force mediated rupture. As such, significant investigation was 
required into the parameters that influence emulsion stability.  
3.1.3 Parameters Influencing Stability of Protein-Stabilized Emulsions 
Stability of the o/w interface, and therefore ease of disruption, is in part dependent 
on the surfactant used. While most emulsions are thermodynamically unstable, interfacial 
tension can be decreased when stabilizing proteins approach the interface from the bulk 
solution, adsorb, alter their conformational structure (depending on the interface), and then 
partition their hydrophilic and hydrophobic regions into the respective phases.107-109 
Protein spreading causes interfacial tension to decrease and interfacial pressure to increase 
until it reaches a plateau, which imparts stability into the system. Proteins that are 
extremely fluid on the interface (i.e. β-casein) will transmit an imposed stress across the 
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interface with a homogenous dissipation and be more resistant to rupture.110 Alternatively, 
globular proteins (i.e. β-lactoglobulin) impose a solid-like structure on the interface. Stress 
on the interface will consequently dissipate heterogeneously, leading to a localized failure 
in the protein layer and subsequent fracture leading to release of payload.110  
System destabilization occurs through coalescence (droplets combining to decrease 
particle concentration and increase particle diameter), flocculation (droplet aggregation), 
creaming or sedimentation (droplets rising or sinking), and ripening (transfer of internal 
phase to a larger droplet demonstrated with an increase in diameter heterogeneity and 
minimal change in particle concentration) to ultimately achieve the energetically favored 
phase separation (Figure 3).109 
 
Figure 3. Destabilization pathways commonly taken by emulsion droplets before 
inevitable phase separation.  
Because bioactive fibrinogen must be used as the surfactant to enable platelet 
adherence and clot targeting, this system is somewhat restricted in regards to surfactant 
choice, pH, and salt concentration. However, emulsion stability can be further adjusted 
through choice of emulsification method. A variety of methods exist to fabricate emulsions 
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with varying energetic input into the system from simple shaking to ultrasonication, 
membrane extrusion, high pressure homogenization, and microfluidic techniques. 95,111-115  
Formation of emulsions is most commonly achieved through vigorously shaking two 
insoluble phases, as often seen in food sciences (i.e. salad dressings). Due to the relatively 
low input of energy, droplet sizes are heterogeneous, macroscopic, and energetically 
unstable leading to phase separation within minutes or hours. For systems requiring greater 
stability and homogeneity, ultrasonication,116 membrane extrusion,117 and high pressure 
homogenization118 are most commonly employed as they are easily scaled up for 
commercial manufacturing purposes. Particle sizes can reach the nanometer length scale, 
imparting substantial stability to the system. Microfluidic techniques include a variety of 
system designs including either polydimethyl siloxane (PDMS) and glass capillary based 
methods. Because the flow rates and channel geometries are precisely controlled for each 
emulsion droplet fabricated, these systems produce extremely homogenous particles in the 
micro- or nano- (if a commercial microfluidizer is used) size range.114 While commercial 
microfluidizers can produce large quantities of emulsion particles at once, laboratory-
scaled single-channel microfluidics that utilize single-droplet generation do not lend 
themselves to commercial scale up as they are resource and time intensive.114  
In this chapter, fibrinogen stabilized emulsions were prepared via homogenization or 
capillary-based microfluidic fabrication methods in order to compare size and stability of 
the resultant particles during storage. A microfluidic device was then optimized in order to 
investigate platelet adhesion onto the emulsion surface and the effect of platelet-contractile 
force on the prepared fibrinogen stabilized emulsion droplets. Platelet-mediated droplet 
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rupture was qualitatively defined as significant morphological disruption and/or significant 
distortion of the interfacial surface layer of fibrinogen. 
 Experimental Approach  
3.2.1 Materials 
Dodecane, sudan black, and BSA were purchased from Sigma-Aldrich (St. Louis, 
MO). PBS, collagen type 1, CellMask Deep Red, CellMask Orange, fibrinogen-Alexa 
Fluor 488 conjugate, heparinated blood collection tubes, and 10% ACD blood collection 
tubes were purchased from Fisher Scientific (Pittsburgh, PA). PDMS (Sylgard 184) was 
purchased from Ellsworth Adhesive Systems (Germantown, WI).  
3.2.2 Methods for Fibrinogen Emulsion Fabrication 
Initial investigations using the following microfluidic emulsification method used 
BSA as a model protein instead of fibrinogen to optimize flow rates, as this was more cost-
effective.  Once conditions were optimized, a 1:1 mixture of fibrinogen and dextran was 
used in order to conserve fibrinogen. However, all dispersions contained 2 mg/mL 
surfactant in 10 mM PBS (ionic strength = 150 mM) as the continuous phase and dodecane 
dyed with sudan black as the oil phase. Images for confocal microscopy also contained 38 
ng/mL fibrinogen-Alexa Fluor 488 conjugate and were polymerized with 0.8 U/mL of 
thrombin. 
3.2.2.1 Capillary Microfluidic Fabrication 
 28
Emulsions fabricated with glass capillary-based microfluidic devices have been 
shown to produce extremely homogenous dispersions, as each emulsion is fabricated 
individually. Three different capillary devices were investigated (Figure 4). To construct 
the capillary devices, first two glass slides were conjoined by epoxying over two small 
pieces of glass. A square glass capillary with inner diameter of 1.0 mm is then secured on 
top of the glass slides with epoxy. A round glass capillary with outer diameter of 1.0 mm 
and inner diameter of 0.58 mm was pulled using a Sutter Instruments pipette puller to 
form two capillaries. The end of the pulled capillary was cut and placed inside the square 
capillary (on the left) for a simple capillary device (Figure 4A). For a capillary co-flow 
device (Figure 4B), an additional round capillary was placed inside the square capillary 
(on the right) so the ends of each capillary slightly overlap. For a capillary co-flow flow-
focusing device (Figure 4C), the second capillary from the pulled capillary was cut so the 
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tip is larger than the first capillary and was placed inside the square capillary (on the 
right) where the tips are ~20-30 μm away from each other.  
 
Figure 4. Representation of phase interactions in (A) capillary, (B) capillary co-flow, 
and (C) capillary co-flow flow-focusing microfluidic devices. 
After all capillaries were in appropriate positions, they were glued to the glass 
with epoxy. Next, plastic short syringe tips were adjusted to fit over the capillaries at 3 to 
4 positions (Figure 5): 1) over the left round capillary, 2) over the left round-square 
capillary junction, 3) over the square-right round capillary junction (for co-flow and co-
flow flow-focusing), and 4) over the right round (exit) capillary. The syringe tips were 
fixed with epoxy, and the device was left to set overnight.  
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Figure 5. Image of a glass capillary-based co-flow microfluidic for emulsion 
fabrication. 
Tubing was fitted to the device via syringe tips. The tubing was then attached to 
syringes loaded with each phase solution. The oil phase entered the device through the 
left round capillary from a 10 mL syringe. The continuous solution entered through the 
capillary junctions (30 mL syringe for the left and 5 mL syringe for the right), and the 
emulsions left through the right capillary, which goes to a collection vial. The syringes 
were placed in syringe pumps.  
For the capillary microfluidic device, the left capillary tip diameter ~40 μm and 
flow rates for the continuous phase were 90 mL/hr and 6 mL/hr for the oil phase. For the 
co-flow device, capillary diameter was around ~40 μm, and flow rates for the left 
continuous phase was 10 mL/min, right continuous phase was 5 mL/hr, and oil was 5 
mL/hr. For the co-flow flow-focusing device, the capillary diameters were ~40 and ~60 
μm for the left and right tips, respectively. Flow rates were maintained at 8 mL/hr for the 
left continuous phase, 100 μL/hr for the right continuous phase, and 800 μL/hr for the oil. 
3.2.2.2 Homogenization 
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For emulsions prepared via homogenization, both continuous and oil phases (10:3 
continuous phase to oil volume ratio) were loaded into a culture tube. The sample was 
homogenized with an Omni International Tissue Master 50 at 15,000 rpm for 30 sec. 
3.2.3 Washed Platelet Collection  
Human blood was drawn according to IRB-approved protocols per the Declaration 
of Helsinki into 20% ACD. To isolate washed platelets, platelet-rich plasma (PRP) was 
first extracted from whole blood via centrifugation. Additional ACD was added to the PRP 
to make a 10% ACD solution before spinning down again to separate platelet-poor plasma 
(PPP) and platelets. The PPP was removed and platelets were resuspended to the desired 
concentration in Tyrode’s buffer and stained with cell membrane stain (CellMask Deep 
Red). 
3.2.4 Development of Microfluidic Assays 
Microfluidic molds were fabricated via standard soft lithography techniques.119 
PDMS was poured into the mold and placed in a 60 C oven overnight. The microfluidic 
was then cut out, entry and exit hole were punched into the channels, and then plasma 
bonded to a clean glass slide. Experiments using Y-channel and straight channel 
microfluidic devices were used without modification before the experiment. Significant 
modification of the device was required for the “Micro Thrombi” microfluidic 
experiments. First, the microfluidic walls are coated with 1 mg/mL collagen type 1 and 
washed with Tyrode’s buffer. Heparinated whole blood with platelets stained with 
membrane stain (CellMask Orange) was perfused through to form platelet aggregates on 
the bottom and walls. The channel was then washed again with Tyrode’s buffer, and 
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fibrinogen emulsions were then perfused through and device flipped 180, which allowed 
the emulsion particles to adhere to the platelet aggregates. The channel was washed once 
more, and a round of concentrated platelets stained with a different membrane stain 
(CellMask Deep Red) suspended in Tyrode’s buffer were perfused through with calcium 
(10 mM), magnesium (2 mM), and ADP. Experiments were monitored with confocal 
microscopy. 
 Results and Discussion 
3.3.1 Investigation of Emulsion Fabrication Method 
An emulsification method that produced a stable dispersion was investigated to 
fabricate fibrinogen emulsions. The emulsification methods investigated included 
homogenization and various glass-based capillary microfluidic devices. BSA was used as 
a model protein for these experiments as to not waste fibrinogen. The basic capillary 
microfluidic device (Figure 6A) is the simplest device to construct; however, extremely 
high flow rates are required consuming an enormous amount of material to produce 
emulsion droplets that are ~100 μm in diameter. This method was deemed unsuitable 
because of the amount of material required, and because the produced emulsions were too 
large and dilute. 
A co-flow capillary device (Figure 6B) was next employed. The resulting 
emulsions were only slightly smaller, and flow rates remained too high to make the device 
feasible for fibrinogen-based emulsions. Finally, a co-flow flow-focusing device (Figure 
6C) was used, which significantly reduced the required flow rates and droplet diameter 
(~50-80 μm in diameter). Because of the large volume of solution still required, 1:1 
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solutions of fibrinogen and dextran were used as a co-surfactant when fibrinogen emulsions 
were made in order to reduce the consumption of fibrinogen.  
 
Figure 6. Brightfield micrographs of glass capillary-based fabrication of 
microemulsions. Images show (A) a standard glass capillary design, (B) a co-flow 
capillary design, and (C) a co-flow flow-focusing capillary design with the oil phase 
jet cone indicated with the red circle. 
Stability studies were conducted comparing emulsions prepared with co-flow flow-
focusing microfluidics and a tissue homogenizer (Figure 7). While microfluidic 
preparation gives a homogenous dispersion of large emulsions, homogenization gives a 
heterogeneous population but particles in the desired size range of ~10-50 μm in diameter. 
Samples from each method were left in the refrigerator at 4 °C for 6 days and compared 
again to determine if significant destabilization events occured. Clearly, both samples 
underwent coalescence. It also appears that some protein aggregation occurred in the 
homogenized sample, possibly due to the high-energy input from emulsification.  
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Figure 7. Emulsions fabricated from glass capillary microfluidics are more stable 
over time, but emulsions made from homogenization enable access to smaller sized 
droplets. Brightfield micrographs at 10x magnification show emulsions made of 
fibrinogen-dextran (1:1) stabilized solutions prepared with (a and c) co-flow flow-
focusing microfluidics and (b and d) homogenization. Images taken (a and b) 
immediately after preparation and (c and d) after 6 days at 4 °C.  
Due to desired particle size, material restraints, and logistical considerations, 
homogenization was chosen as the emulsification method for experiments involving 
platelet contraction. Emulsification and surface adsorption was not seen to affect protein 
structure in such a way as to interfere with thrombin cleavage and fibrin formation. 
Confocal images taken after thrombin addition clearly show fibrin fibers growing off the 
interface and incorporating emulsions (Figure 6). 
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Figure 8. Interfacial fibrinogen enables droplet integration into fibrin networks. 
Confocal micrographs of (a) fibrin fibers, (b) a fibrinogen emulsion (no thrombin), (c 
and d) fibrin coated emulsions (thrombin added), and (e and f) emulsion encapsulated 
in fibrin fibers.  Fibrin (green) labeled with fibrinogen-Alexa Fluor 488 conjugate. 
3.3.2 Development of an Assay to Investigate the Effects of Platelet Contractile Force on 
Emulsion Particles 
Several experimental designs were considered and attempted in order to achieve 
platelet adhesion to emulsion particles, platelet contraction, and visualization of emulsion 
disruption. Static macroscopic experiments were first attempted wherein platelets and 
fibrinogen emulsions were exposed to thrombin in a vial. It was hypothesized that the oil 
phase would leave the forming clot and rise to the top, indicating platelet-induced emulsion 
rupture had occurred. However, this was never observed possibly because the oil droplet 
would potentially get trapped in the forming clot and not separate out into a distinct phase. 
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Static microscopic experiments were then conducted wherein emulsions and 
platelets were subjected to thrombin in a cover well and observed with confocal 
microscopy. Several problems were uncovered at this stage: platelets were not always 
adhered to emulsions, contraction of the model clot did not always occur, and a significant 
density issue was realized where emulsions, being less dense than water, persisted at the 
top of the system and platelets, being denser, sank to the bottom. It is believed that the 
difference in densities was likely a factor in why platelets were not adhering to the 
emulsions in this experimental setup.   
To create a more physiologic environment, microfluidics where then used to 
monitor platelet adhesion and contraction at the emulsion surface under flow. A Y-
shaped microfluidic was first utilized in which washed platelets, fibrinogen (2 mg/mL), 
calcium (10 mM), magnesium (2 mM), and fibrinogen stabilized emulsions were 
perfused through the top channel, and thrombin (1 U/mL) was perfused through the 
bottom channel. While contraction of the clot formed at the Y-channel juncture can be 
seen, the channels were not wide enough to allow emulsions to flow through and the 




Figure 9. Confocal micrographs of microfluidic experiments investigating platelet 
adhesion and contraction on fibrinogen stabilized emulsions. A Y-channel device (A) 
was used in the presence of thrombin as well as a straight channel device in the 
presence of ADP. The immobilized emulsion droplets can be seen before perfusion of 
washed platelets (B) and after platelet aggregation onto the emulsion droplets (C). 
Fibrinogen can be seen in green (Alexa Fluor 488) and platelets can be seen in orange 
(membrane stain). 
In order to address these issues, a microfluidic straight channel device was used 
with channels of 200 μm in diameter to ensure particle passage. Additionally, fibrinogen 
emulsions were perfused through before any activators or platelets, flipped over, and 
incubated on the glass. Before the experiment began, the device was flipped back over so 
the emulsions were adhered onto the glass slide on the bottom of the device (Figure 9B). 
ADP was perfused with washed platelets instead of thrombin in order to avoid device 
clogging.  
Substantial platelet aggregation was seen on the immobilized emulsion droplets, 
creating tail-like aggregates throughout perfusion (Figure 9C). Platelet contraction of these 
aggregates was seen towards the end of the experiment; however, distinct emulsion 
disruption was still an elusive event. It was hypothesized that the experimental design was 
too reductionist in nature. The clotting environment is extremely dynamic wherein 
entrapped platelets are contracting in different times frames and to different extents due to 
the heterogeneity of substrate stiffness within a clot, concentration of soluble clotting 
activators, and time of adhesion and activation. The straight channel experimental design 
only enables platelet contractile force to be exerted in one direction relative to the emulsion 
particle. To utilize a design more aligned with physiologic conditions, a “micro thrombi” 
design was developed and implemented. This design allows for the emulsion particles to 
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adhere to a more physiologic substrate and for contraction to be exerted in two directions. 
These experiments used calcium and either thrombin or ADP as the platelet agonist.  
In development of the “micro thrombi” assay, confirmation that micro thrombi 
could form via perfusion of heparinated whole blood through a collagen coated 
microfluidic channel as well as the ability of emulsion particles to adhere to immobilized 
micro thrombi was necessary. It is clear from qualitative analysis of the microfluidic device 
before perfusion of the second round of platelets that micro thrombi do form and fibrinogen 
stabilized emulsions do adhere to them (Figure 10).  
 
Figure 10. Confocal micrographs of "micro thrombi" assay device after fibrinogen 
(Alexa Fluor 488, green) emulsions were incubated onto the micro thrombi (platelets, 
cell membrane stain, red) demonstrate that droplets adhere to the platelet aggregates. 
(A) A micrograph showing the cross-section of only green and red channels are 
demonstrate emulsions adhere onto the micro thrombi in the Z direction. Micrograph 
of all channels merged (B) show numerous micro thrombi with adhered emulsions.  
3.3.3 Platelet Contractile Force-Mediated Emulsion Disruption 
 39
After micro thrombi formation and targeted emulsion adherence was confirmed, 
the second round of washed platelets were perfused through the device along with platelet 
activators. Platelets clearly adhere to the fibrinogen coated surface, form large aggregates, 
and contraction can be seen throughout the aggregate (Figure 11). This contraction induces 
significant morphological disruption of the emulsion particle, changing its shape from 
circular to ovicular. Furthermore, the fibrinogen on the particle surface is ruptured resulting 
in a bare interfacial surface for half of the emulsion particle. These qualitative changes in 
the emulsion demonstrate that the contractile force of adhere platelets is substantial enough 
to invoke significant particle disruption. 
 
Figure 11. Perfusing platelets adhere to emulsion droplets, rupture the fibrinogen 
stabilizing layer, and deform droplet morphology. Progression of platelet aggregation 
(membrane stain, blue) on fibrinogen (Alexa Fluor 488, green) emulsions at (a and d) 
0 minutes, (b and e) 10 minutes, and (c and f) 18 minutes using ADP as the platelet 
activator. Micrographs (a – c) show all channels merged and (d – f) show green 
channel only. Arrows indicate forming platelet aggregates.  
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This behavior was again seen in experiments using thrombin as the platelet 
activator (Figure 12). There is clear and significant destruction of the fibrinogen interfacial 
surface of the emulsion along with deformation of the emulsion droplet. As before, the 
contractile force of the platelet aggregated “pushed” the oil droplet away from the 
aggregate, but it does not get “released” from the fibrinogen/platelet aggregate.  
 
Figure 12. Only droplets with adhered platelets exhibit altered distribution of 
fibrinogen coating and morphological changes. Confocal micrographs of platelet 
(membrane stain, blue) induced fibrinogen (Alexa Fluor 488, green) emulsion droplet 
disruption using thrombin as the platelet activator. Micrographs show the split (a) 
green channel, (b) blue channel, (c) brightfield, and (d) all channel merged. 
Upon further qualitative analysis, a difference in aggregation profiles can be seen 
depending on emulsion size; platelets aggregate behind small emulsions forming “tails” 
but in front of large emulsions forming “wings”. This behavior is likely due to a larger dead 
zone in fluid flow in front of larger emulsions, allowing platelets to travel on the outskirts 
of the dead region and aggregate in the front (Figure 13). Presumably, smaller emulsions 
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would create smaller dead zones closer to the size scale of individual platelets, allowing 
them to pass over the emulsion. As they traverse the emulsion, the higher fluid velocity 
prevents them from adhering to the fibrinogen on the top, so they continue to slide along 
the surface until they are behind the emulsion where they can aggregate. A tail forms with 
continued aggregation as the platelets travel from emulsion surface to the back of the 
platelet aggregate. 
 
Figure 13. Illustration demonstrating the effects of emulsion size on fluid flow and 
platelet aggregation profile. Top – large dead zone allows platelets (blue) to adhere in 
front of the ~50 μm emulsion (green) and aggregate in a wing-like pattern. Bottom – 
smaller dead zone forces platelets to traverse over the ~10 μm emulsion and aggregate 
in the dead zone behind the emulsion in a tail-like pattern. Red platelets represent 
micro-thrombi adhered on a collagen layer (orange). 
 Conclusions 
Fibrinogen stabilized emulsions can easily be fabricated via homogenization or 
capillary microfluidics without significant loss of bioactivity. While capillary microfluidics 
yields homogeneously sized emulsions, homogenization yields emulsions within a feasible 
size range for drug delivery. Fibrinogen stabilized emulsions fabricated via 
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homogenization were thus used to investigate the feasibility of platelet contractile force-
mediated rupture as a drug delivery paradigm. 
Several assay designs were developed to investigate this behavior on a qualitative 
level. Static co-incubation, Y-channel microfluidics, and straight channel microfluidics all 
exhibited deficiencies including density-mediated separation of platelets and emulsions 
and microchannel clogging. However, the “micro thrombi” assay was effective in 
demonstrating platelet adhesion and aggregation onto the emulsion surface, platelet 
aggregate contraction, and significant particle disruption in regards to the particle 
morphology and fibrinogen surface coverage. Because of the hydrophobic nature of 
emulsions, it is not possible to visualize a “release” of the interior phase because it is not 
soluble in the continuous phase (buffer). 
From observations of experiments conducted with the “micro thrombi” assay, it can 
be concluded that: (1) platelets adhere to microparticles that display fibrinogen on their 
surface, and (2) that platelet contractile force is sufficient enough to rupture a microparticle 
surface. Thus, a platelet-mediated drug delivery paradigm that leverages the contractile 
force of activated platelets is feasible.  
While emulsions were effective model particles to investigate the feasibility of this 
system, they do not lend themselves well to delivery of clot augmenting biotherapeutics. 
The majority of target drugs for clot augmenting applications are recombinant or plasma-
derived proteins that are not soluble in oil phases. As such, the subsequent chapters 
investigate the development of a suitable drug carry nanoparticle for the application of this 
drug delivery paradigm for clot augmentation.  
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CHAPTER 4. MODIFICATION OF POLYELECTROLYTE 
MULTILAYER CAPSULES TO ENABLE PLATELET- 
MEDIATED RUPTURE 
Results described in this chapter regarding development and characterization of the 
optimized PEM capsule have been reported in ACS Nano.1 
 Polyelectrolyte Multilayer Capsules 
The layer-by-layer (LbL) deposition method was first reported by Iler et al. in 1966 
for the fabrication of ultra-thin films using colloidal particles of opposite charge that were 
deposited onto glass in an alternating fashion and held together through electrostatic 
interactions.120 Decher et al. expanded on the LbL assembly method using oppositely 
charged polyelectrolytes to fabricate polymer-based ultra-thin films.121 Cationic 
polyelectrolytes that have been used in LbL assembly of ultra-thin films include 
poly(allylamine), poly(diallyldimethylammonium) (PDADMAC), and poly-L-lysine 
(PLL). Anionic polyelectrolytes that have been used include poly(styrene sulfonate), 
dextran sulfate, and poly-L-glutamic acid (PLG).   
While initial investigations in the field focused on assembly onto planar substrates, 
polyelectrolyte LbL assembly has also been developed using colloidal particles as the 
substrate.122-124 If a sacrificial colloidal substrate is used, it can be removed after the desired 
number of layers have been deposited such that the sacrificial colloidal substrate was used 
to template the assembly of a hollow PEM capsule typically in the size range of 1-10 m 
in diameter. Such sacrificial cores can be organic or inorganic in composition and include 
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melamine formaldehyde, polystyrene, calcium carbonate, or mesoporous silica.125-127 The 
cores can be dissolved by suspending the particles in an acidic solution, organic solvent, 
or solution containing a chelating agent (i.e. ethylenediaminetetraacetic acid (EDTA)). 
A substantial advantage in utilizing the LbL assembly technique is the facile manner 
in which particle properties can be tuned. Polymer shell thickness can be most easily tuned 
by modulating the number of polyelectrolyte layers deposited and the solution conditions 
during the deposition step (i.e. salt concentration and pH).128 Shell thickness not only 
affects the mechanical robustness of the particle (fewer layers yields a softer capsule), but 
also the diffusive release profile of a chemical species loaded within the capsule 
interior.27,129,130 Changing the chemical composition of the polyelectrolytes used is another 
facile manner in which application specific modifications can be incorporated. For 
example, biocompatible polyelectrolytes can be used if the particle is being developed for 
biological applications (PDADMAC versus poly-L-arginine). Several commonly used 
polyelectrolytes can be covalently modified to include moieties (small molecules or peptide 
sequences) to target the PEM capsule to specific biological sites, functional groups to 
enable cross-linking between the polymer layers, and enhance drug retention.131-133 
Nanoparticles and proteins can also be non-covalently included within appropriate 
polyelectrolyte layers through their surface charge to effect particle targeting or additional 
behaviors.52,134,135 Because of the facile and vast manners in which to tune PEM capsules 
for a specific application, these particles have been heavily investigated for applications as 
imaging agents,136,137 sensing materials,138 microreactors,139 and of particular importance 
to this work, drug delivery.140-142 
4.1.1 PEM Capsules for Drug Delivery 
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PEM capsules for the delivery of small molecules and proteins have been developed 
by loading the therapeutic into the interior of the capsule.55,143-146 This can be accomplished 
through co-precipitation in the sacrificial templating core if calcium carbonate is used or 
via diffusion through the PEM capsule wall after fabrication and core removal.26,147,148 
Efficiency of encapsulation for the diffusion-based method is highly dependent on pH and 
salt concentration of the loading solution, as it has been shown that the permeability of the 
PEM capsule wall can be heavily influenced through protonation state, salt screening, and 
the charge of the loading molecule.149  
As mentioned above, these particles have held particular interest for targeted drug 
delivery. Several strategies have been employed that require decoration of the surface with 
a targeting moiety (i.e. antibody, peptide, or magnetic nanoparticles). An antibody 
targeting mechanism was employed by Deo et al. by functionalizing the surface of poly-
L-arginine and dextran sulfate microcapsules with Protein G via Biotin/Streptavidin.150 
Anti-collagen type IV or anti-fibronectin antibodies then readily adhered to the Protein G 
microcapsule surface, enabling antibody-specific targeting of collagen type IV or 
fibronectin coated substrates, respectively.  
The well-established RGD peptide sequence was implemented for targeting of DQ-
ovalbumin (model therapeutic cargo) encapsulated microcapsules by Costa et al.151 
Polyelectrolyte microcapsules fabricated from chitosan and elastin-like recombinamers 
that displayed either RGD or a scrambled RGD sequence (control) were co-incubated with 
human mesenchymal stem cells for 3 days. The investigators showed that, while cellular 
uptake for both microcapsules types were not significantly different, microcapsules 
displaying RGD resulted in higher intracellular bioavailability of DQ-ovalbumin.  
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Pavlov et al. included magnetite nanoparticles into the polyelectrolyte layer of 
microcapsules fabricated from LbL assembly of poly-L-arginine and dextran sulfate to 
enhance cell targeting for drug delivery in the presence of a magnetic field.135 The authors 
investigated the intracellular delivery of luciferase enzyme and plasmid DNA into human 
embryonic kidney epithelial cell line 293T cells and showed 25 fold increase in enzyme 
activity and 3.4 fold increase in transfection compared to microcapsules without magnetite 
nanoparticles.   
Once at the target site, a variety of mechanisms have been developed for release of 
the encapsulated therapeutic. These include application of ultrasound, redox responsivity, 
and enzymatic biodegradation to deliver the drugs more quickly than a diffusion-based 
mechanism would allow. Gao et al. embedded fluorescence carbon dots into the PEM wall 
of a poly(allylamine) and poly(styrene sulfonate) microcapsule via a hydrothermal 
reaction.134 After application of ultrasound for 5 minutes, the authors demonstrated a 80% 
release of the fluorescent carbon dots from the PEM microcapsule.  
To leverage the intracellular redox environment of cancer cells, a poly-L-arginine 
and dextran sulfate based microcapsule utilized a glutathione responsive disulfide 
crosslinker to conjugate doxorubicin directly to the poly-L-arginine in the PEM wall.152 
The investigators showed a higher therapeutic effect than free doxorubicin in HeLa cells 
due to sustained and site specific doxorubicin release.  
In a later work, Timin et al. reported a triple responsive (UV, ultrasound, and 
enzyme sensitive) microcapsule for enhanced retention of encapsulated small molecule 
therapeutics in non-target areas.55 These microcapsules were fabricated from poly-L-
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arginine and dextran sulfate and employs a sol-gel approach to impart a SiO2/TiO2 coating 
on the microcapsule, which enhances small molecule retention and imparts UV light and 
ultrasound sensitivity. Release of encapsulated rhodamine B as a model small molecule 
was systematically investigated for each stimulus and compared to release without the 
stimulus. The investigators demonstrated a 60% increase in release for UV irradiated 
samples after 80 minutes, 80% increase in release after 180 seconds of sonication, and 30% 
increase in release after 27 hours of enzyme exposure.  
Clearly, there is a large volume of work developing and tuning these constructs for 
drug delivery applications. While PEM microcapsules are easily optimized for a specific 
disease application, the targeting and delivery strategies that have been utilized, while well-
established and well-characterized, are not novel in the field of drug delivery. In many 
cases, they are somewhat cumbersome as they require additional equipment or substantial 
time frames for delivery of the full dose. An increasing amount of research is being 
conducted on the integral role of the cellular biomechanical behavior in various 
diseases.153,154 Leveraging the biomechanical behavior of cells presents as an elegant 
delivery method, wherein immediate delivery of a drug can be achieved at a target site 
without the need of external equipment.  
4.1.2 Influence of Cellular Mechanics on PEM Capsules 
A subset of research within the field investigating PEM microcapsules for drug 
delivery applications has focused on characterizing the deformability of these particles 
when subjected to an applied force.27,130,155-158 Of particular importance to drug delivery, 
these studies have elucidated the forces necessary to result in release of an encapsulated 
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model therapeutic cargo for different microcapsule architectures.158 Recently, these studies 
have been conducted to characterize the particle’s response to applied force in order to 
avoid rupture and drug release during cellular uptake events, so the full dose of the 
encapsulated drug is delivered to the target site inside the cell.27,130 
Delcea et al. investigated the force-induced deformation of PEM microcapsules 
fabricated from 4 double layers of PDADMAC and poly(styrene sulfonate) and subsequent 
release of encapsulated dextran-fluorescein isothiocyanate (FITC) molecules.130 
Microcapsule deformation and release was quantified after being loaded into Vero cells via 
electroporation, which was then correlated to deformation and release witnessed during 
atomic force microscopy colloidal probe experiments. The authors concluded that a force 
of at least 200 nN is applied to the PEM microcapsules during intracellular uptake, which 
resulted in nearly 75% release of encapsulated dextran-FITC due to roughly 20% total 
deformation of the particle. 
Building upon this experiment, Palankar et al. investigated deformation of PEM 
microcapsules fabricated from non-biocompatible polyelectrolytes (poly(styrene 
sulfonate) and poly(allylamine) and microcapsules fabricated with varying layer number 
of biocompatible poly-L-arginine and dextran sulfate.27 As in the previous investigation, 
an atomic force microscopy colloidal probe was used to ascertain mechanical stability of 
non-biocompatible and biocompatible PEM microcapsules. The non-biocompatible PEM 
microcapsules were mechanically more stable, exhibiting plastic deformation at 40% 
applied deformation compared to 20% for biocompatible PEM microcapsules, possibly due 
to stronger electrostatic interactions between PEM layers of the non-biocompatible 
polyelectrolytes. The authors then calculated force-deformation curves for biocompatible 
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PEM microcapsules fabricated with 4, 8, and 12 PEM layers. Microcapsules with 4 layers 
were the most deformable, exhibiting 30% deformation at an applied force of 200 nN. This 
was consistent with qualitative examination of PEM microcapsule deformation after cell 
internalization. 
 These investigations demonstrate that not only can the biochemical properties be 
readily tuned, but that the mechanical properties of PEM microcapsules can be modified 
to exhibit responsive behavior within a relevant range of forces exerted by cells. In 
developing a new paradigm that utilizes platelet biochemical and biomechanical behavior 
to sense vehicle targeting and actuate drug release, the ease in modification of these particle 
parameters make them extremely attractive while optimizing the system to display the 
desired functionalities. Moreover, as PEM capsules contain an aqueous core, these make 
them applicable to deliver clot-augmenting biotherapeutics. As such, PEM microcapsules 
were subsequently developed to (1) include fibrinogen to enable platelet-microcapsule 
hybridization and clot targeting, and (2) rupture and release the full drug cargo when 
hybridized and nearby platelets contract at sites requiring hemostatic augmentation.    
 Experimental 
4.2.1 Materials 
PLL hydrobromide (30-70 kDa), PLG sodium salt (50-100 kDa), dextran (70 kDa), 
MES, NaCl, dextran-fluorescein isothiocyanate (FITC) (70 kDa), dextran-rhodamine B 
isothiocyanate (RBITC) (70 kDa), EDTA, sodium bicarbonate, Sigmacote, calcium 
chloride, magnesium chloride, and sodium carbonate were purchased from Sigma-Aldrich 
(St. Louis, MO). PBS, human fibrinogen-AlexaFluor 488, CellMask Deep Red, collagen 
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type 1, rhodamine B isothiocyanate (RBITC), CD41a-APC, and acid citrate dextrose 
(ACD) blood collection tubes were purchased from Fisher Scientific (Pittsburgh, PA). 
Recombinant human alpha thrombin was purchased from Haematologic Technologies 
(Essex Junction, VT). Human fibrinogen was purchased from Enzyme Research 
Laboratories (South Bend, IN). Float-a-lyzer dialysis tubes (10 kDa MWCO) were 
purchased from Spectrum Labs (Rancho Dominguez, CA). PAC-1-FITC was purchased 
from BD Biosciences (San Jose, CA).  
4.2.2 Washed Platelet (WP) Collection  
Human blood was drawn according to IRB-approved protocols per the Declaration 
of Helsinki into 20% ACD. To isolate WPs, PRP was first extracted from whole blood via 
centrifugation. Additional ACD was added to the PRP to make a 10% ACD solution before 
spinning down again to separate PPP and platelets. The PPP was removed and platelets 
were resuspended to the desired concentration in Tyrode’s buffer and stained with 
CellMask Deep Red. 
4.2.3 PEM Capsule Fabrication 
Calcium carbonate cores used to template the fabrication of PEM capsules were 
synthesized according to the literature by mixing equal volumes of 0.33 M calcium chloride 
and 0.33 M sodium carbonate for 30 seconds. Typically, 7 mL of each salt solution was 
added. Stir was then ceased, and the solution was left to stand for 10 minutes, followed by 
washing with DI water 3x and drying over vacuum using a Buchner funnel with fritted 
disc. A typical yield of 190-210 mg was achieved (83-91% yield). For cores loaded with 
dextran-RBITC, 5 mg of dextran-RBITC was added to the calcium chloride solution before 
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addition of sodium carbonate. For double cores with encapsulated dextran or dextran-FITC 
in the outer core layer, the above-fabricated cores were dissolved in DI water at 80 mg/mL. 
To the stirring core solution, 1 mL of 0.33 M sodium carbonate and 1 mL of 0.33 M calcium 
chloride with 5 mg dextran or dextran-FITC were simultaneously added. Stir was continued 
for 30 seconds, and then the solution was left to stand for 10 minutes. Cores were washed 
3x with DI water and dried over vacuum. A typical yield of 93 mg (83%) was achieved. 
To make the PEM capsules, 2 mg/mL solutions of PLL and PLG were made with 
0.5 M NaCl, pH 6.25. Polyelectrolyte layers were deposited onto the cores with alternating 
charge in a LbL fashion. A 2% w/v solution of cores was dispersed in the PLL solution for 
10 minutes. The cores were then pelleted at 200 x g for 5 minutes and washed 3 times with 
0.5 M NaCl pH 6.25 before the next layer was deposited. When the desired number of 
layers was deposited, the cores were dispersed in a 0.2 M EDTA solution at pH 6.25 for 
30 minutes to remove the calcium carbonate. The PEM capsules were then washed and 
pelleted several times (400 x g for 10 minutes, without acceleration or brake) with 5 mM 
MES pH 6.25 and stored at 4 °C until use. Synthesis resulted in 7-9 million particles/mL 
as determined via Beckman Coulter cell counter. 
4.2.4 Zeta Potential  
Samples were diluted with DI water at a 1:9 ratio. Each sample was measured 3 
times at 20 runs for each measurement. Zeta potential of cores during polyelectrolyte 
deposition was measured with a Malvern Zetasizer Nano Series (Malvern, UK). 
4.2.5 Platelet Activation 
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To coat the glass beads with fibrinogen, the LbL deposition technique was used to 
deposit a single PEM onto the glass beads consisting of PLL as the first layer and a 1:1 
solution of PLG and fibrinogen as the outer layer. To fabricate the hybridized 
microparticles, 0.5 mL of a 1 million/mL solution of either PEM capsules or glass beads 
was added to 0.25 mL washed platelets (120 million/mL) stained with CellMask Deep Red. 
The solution was recalcified with 5 mM calcium and 2 mM magnesium and gently mixed 
for 10 minutes. Then 50 uL of Annexin V Alexa Fluor 488 or 100 uL of PAC-1-FITC was 
added before imaging. Images were taken via confocal laser scanning microscopy using a 
Zeiss LSM 700 system (Thornwood, NY). PAC-1-FITC and CellMask Deep Red 
intensities were determined in Image J.  
4.2.6 “Clot-like” Gels  
Static fibrin clot experiments were fabricated by mixing 2 mg/mL fibrinogen (pre-
warmed), 1 U/mL thrombin, 10 mM calcium, 2 mM magnesium, washed platelets stained 
with CellMask Deep Red, and PEM capsules on a glass slides treated with Sigmacote. 
Clots were formed at 37 °C and 60% humidity and imaged via confocal laser scanning 
microscopy using a Zeiss LSM 710 NLO system (Thornwood, NY). 
 Results and Discussion 
4.3.1 Platelet Adhesion onto PEM Capsules and Integration into Fibrin Networks 
The polymers PLL and PLG were used as the positive and negative polyelectrolytes 
of the PEM microcapsule (Figure 14A). The polyelectrolytes are deposited onto calcium 
carbonate cores in a LbL fashion. Calcium carbonate was chosen as the sacrificial core due 
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to its relatively inert removal with EDTA (Figure 14B). As fibrinogen is deposited in a 1:1 
ratio with PLG for the last polyelectrolyte layer, it was assumed an acid or organic solvent 
treatment to remove a mesoporous silica or polystyrene core would substantial lower the 
bioactivity of the protein.  
 
Figure 14. Schematic of LbL assembly of PEM capsules. (A) The polyelectrolytes 
poly-L-lysine (PLL) and poly-L-glutamic acid (PLG) were used to fabricate the PEM 
capsule. (B) Polyelectrolytes were deposited onto a calcium carbonate core, with the 
last layer consisting of 1:1 ratio of fibrinogen and PLG. The core is then removed with 
EDTA to yield capsules with an aqueous core and fibrinogen surface for platelet 
adhesion. 
 Calcium carbonate cores were fabricated via a precipitation reaction by rapidly 
mixing sodium carbonate and calcium chloride for 30 seconds, followed by 10 minutes of 
resting before washing over vacuum. Core size can be modified by adjusting stir speed 
(faster speeds yield smaller particles), the duration of time before stir is started after 
solutions are combined (longer durations yield larger particles), and salt concentration 
(higher concentration yields smaller particles).159  The size of the final PEM microcapsule 
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is predominately determined by the size of the templating particle. Calcium carbonate cores 
used in these investigations were fabricated from 0.33 M calcium chloride and sodium 
carbonate at a stir speed of 600 rpm or 400 rpm to produce particles in the size range of 3 
to 6.5 m in diameter (Figure 15A,B), respectively.  
 
Figure 15. LbL assembly of polyelectrolytes onto calcium carbonate cores yields PEM 
capsules after core removal. (A,B) Brightfield micrographs of calcium carbonate 
cares are shown demonstrating variation of core size dependent on reaction 
conditions. Polyelectrolytes were deposited onto the calcium carbonate core in a LbL 
fashion, which can be confirmed through the zeta potential of the particle (C) after 
each deposition step (n = 3). Confocal micrographs of a cross section (D) and 3D 
rendering (E) of PEM capsules (red, PLL-RBITC) after fabrication show fibrinogen 
(green, Alexa Fluor 488) is localized to the exterior surface of the capsule.  
 To fabricate the PEM capsules, the polyelectrolytes are deposited onto the calcium 
carbonate templating core in an LbL fashion, beginning with the deposition of PLL. The 
zeta potential was taken throughout the fabrication process. The alternating charge of the 
particle after each deposition step suggest that the desired number of layers were, in fact, 
deposited onto the particle surface (Figure 15C). A total of 3 PEM bilayers were deposited 
as this (1) allows the fibrinogen to be on the exterior of the capsule (Figure 15D,E) as it 
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displays a negative charge at physiologic pH (thereby necessitating inclusion in the 
negative layer), and (2) imparts enough mechanical stability for processing. Particles with 
2 PEM bilayers were initially investigated, but could not withstand the purification steps 
via centrifugation after the calcium carbonate template was removed with EDTA. 
 Once it was confirmed that fibrinogen was localized to the exterior of the capsule 
surface, the PEM capsules were mixed with washed human platelets and monitored with 
confocal microscopy to ascertain if the platelets adhered to the PEM capsule surface. 
Confocal images show that individual platelets do adhere to the surface of PEM capsules 
to form platelet-hybridized PEM capsules (HyPEMs) (Figure 16A). Furthermore, confocal 
images of “clot-like” gels fabricated from fibrinogen, washed human platelets, and 
thrombin show that platelet-HyPEMs also adhere to large platelets aggregates (Figure 16B) 
and integrate into fibrin networks (Figure 16B-D). This qualitative data suggests displaying 
fibrinogen on the exterior enables the “targeting” mechanism of this drug delivery 




Figure 16. Fibrinogen on the surface of PEM capsules enables platelets to adhered to 
PEM capsule and polymerize into fibrin networks. Confocal micrographs show that 
platelets (blue, cell membrane stain) adhere to the surface of PEM capsules (red and 
green, PLL-RBITC and fibrinogen Alexa Fluor 488) to form platelet-hybridized PEM 
capsules (HyPEMs) (A). Furthermore, these constructs adhere to platelet aggregates 
(B) and polymerize into fibrin (green, Alexa Fluor 488) networks (B-D). 
 While it is not surprising that no PEM capsule rupture can be seen in Figure 16A 
in the absence of platelet agonists, it is surprising that no PEM capsule disruption can be 
seen in Figure 16B-D, in which thrombin is present. This experiment was repeated several 
times at various platelet and fibrinogen concentration; however, little PEM capsule 
disruption was qualitatively witnessed. Loss of circularity was occasionally seen (Figure 
17A); however, this could not be considered conclusive rupture. Additional evidence 
supporting the potential of PEM capsules to rupture due to platelet contractile forces is 
seen in the confocal micrographs in Figure 17B,C. It appears the contraction of the 
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opposing platelets tethered to the PEM capsule via fibrin fibers Figure 17B tore the bottom 
capsule open. Similarly, in Figure 17C, disruption of the PEM layer can be seen due to 
several contracting platelets around two PEM capsules. While this was not a commonly 
viewed event, this does support the hypothesis that platelet contractile force is sufficient to 
physically rupture PEM capsules.  
 
Figure 17. Evidence of morphological disruption of PEM microcapsules in "clot-like" 
gels. Confocal micrographs showing (A) morphological change from circular to 
ovicular of PEM capsules (red, PLL-RBITC) being contracted upon by two 
hybridized platelets (blue, cell membrane stain) within a fibrin (green, Alexa Fluor 
488) network. Rupture of PEM capsules can also be seen between two opposing, 
contracting platelets that are tethered to the capsules (B). This can more clearly be 
seen in the inset with the green channel removed. Morphological disruption and 
possible rupture can also be seen due to hybridized platelet contraction (C). 
 These experiments were repeated, but PEM capsules loaded with fluorescently-
tagged dextran were used instead of empty PEM capsules. It was hypothesized that, 
perhaps, rupture may be occurring but may not always result in an obvious perturbation of 
the capsule morphology to such an extent that it can be detected through qualitative 
analysis with confocal microscopy. If rupture is occurring with dextran loaded capsules, it 
was hypothesized that it would result in release of the fluorescent dextran, which will be 
easier to detect via confocal microscopy.  
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 Dextran was encapsulated into the calcium carbonate cores by including dextran-
FITC into the calcium chloride solution during the precipitation step. After polyelectrolyte 
deposition and core removal, dextran-FITC is retained in the capsule interior. The PEM 
capsules were mixed with fibrinogen, human washed platelets, and thrombin as before. 
While there was not an overwhelming amount of dextran release, there were events 
providing additional qualitative support for utilization of PEM capsules for this drug 
delivery paradigm.  The confocal micrograph in Figure 18A shows that a portion of the 
PEM capsule walls is getting essentially pulled off of the capsule via contracting fibrin 
fibers. More compelling evidence is seen in Figure 18B, wherein a platelet is contracting 
on the PEM capsule and release of the dextran can be seen out of the “back” of the capsule. 
 
Figure 18. Release of encapsulated dextran from PEM capsules in "clot-like" gels. 
Confocal micrographs demonstrate rupture of PEM capsules (red, PLL-RBITC) 
loaded with dextran (green, FITC) via (A) contracting fibrin (green, Alexa Fluor 488) 
and (B) hybridized platelets (blue, cell membrane stain). (B) Dextran can be seen 
release from the rupture PEM capsule due to platelet contractile force.   
 While the dextran loaded PEM capsules resulted in more compelling evidence than 
the empty PEM capsules that they can be ruptured with platelet contractile forces, the 
number of rupture or release events was still slim – approximately 2-4 events every 200 uL 
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of gel. At this point, it was hypothesized that the highly charged characteristic property of 
the polyelectrolytes themselves could be interfering with release of an encapsulated cargo 
if the PEM capsule was ruptured.  
4.3.2 Structural Modification of PEM Capsule to Enable Platelet-Contraction Mediated 
Release 
To separate the highly-charged PEM wall from the encapsulated cargo and mitigate 
electrostatic interactions between the two, a layer of dextran was included into the PEM 
capsule between the PEM wall and encapsulated cargo. This was accomplished by 
employing a double core strategy wherein the calcium carbonate cores were fabricated as 
before (empty or with encapsulated cargo) but then used again as a seed particle for a 
second precipitation reaction with the inclusion of dextran (Figure 19).1  After LbL 
assembly and EDTA removal of the core, dextran is retained as a thin layer separating the 
core cargo from the PEM wall.   
 
Figure 19. The double core strategy enables inclusion of a dextran layer to separate 
the encapsulated cargo from the PEM wall. An initial calcium carbonate core is made 
and then used as a seed particle for a second precipitation reaction to include dextran 
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in an outer layer of the core. LbL deposition of polyelectrolytes proceeds as in the 
previous method to fabricate PEM capsules with an internal dextran layer. 
Dextran-RBITC was encapsulated in the inner core region while dextran-FITC was 
encapsulated in the outer core region (Figure 20A,B). The inner calcium carbonate core is 
3.9 ± 0.4 µm in diameter (calculated via Image J, n=102) and increases to 4.7 ± 0.4 µm 
(calculated via Image J, n=101) when the outer calcium carbonate layer with encapsulated 
dextran was deposited.1 After core removal, the dextran is retained as a thin layer in 
between the PEM wall and encapsulated cargo (Figure 20C,D) without mixing, further 
suggesting there exists a certain degree of non-covalent interaction between the PEM wall 
and molecules adjacent to it within the aqueous core. After deposition of 6 polyelectrolyte 
layers (3 PEM bilayers), PEM capsules exhibited a diameter of 5.1 ± 0.4 µm (calculated 
via Image J, n=105) after chelation of the calcium carbonate core.1  
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Figure 20. Utilizing double calcium carbonate cores as templating particles enables 
inclusion of a dextran layer to shield the encapsulated biotherapeutic payload from 
the highly charged PEM. Confocal micrographs (A,B) show morphology of the double 
calcium carbonate core with dextran-RBITC (red) loaded in the inner core region 
and dextran-FITC (green) loaded in the outer region. A 3D rendering of a single 
double core is shown in the inset of B. The final PEM capsules retain dextran both 
from the inner and outer core regions in their respective areas (C,D). All scale bars = 
5 μm. The zeta potential (E) was ascertained throughout the fabrication process, 
demonstrating a statistically significant difference in charge after the first layer is 
deposited between single core and double core (p<0.001), single core and adsorbed 
dextran (p<0.001), and double core and adsorbed dextran (p<0.05). Additionally, 
there is a significant difference in charge after the second layer is deposited between 
using a single core and adsorbed dextran (p<0.05), n = 3. Statistical significance: * 
p<0.05, *** p<0.001. 
The zeta potential was again determined to ascertain if inclusion of dextran altered 
deposition of polyelectrolyte layers (Figure 20E) throughout the fabrication process by 
altering the surface charge of the calcium carbonate core particles. Double cores with 
encapsulated dextran in the outer layer and single cores with adsorbed dextran (as an 
additional method) were compared to single cores used previously. Adsorbing dextran onto 
the core surface decreases the absolute value of the zeta potential while encapsulating it in 
the outer core results in roughly the same zeta potential as the single core. After deposition 
of the first polyelectrolyte layer (PLL), the zeta potential of both the double core and 
adsorbed core were significantly lower than the single core (p<0.001), and the adsorbed 
core was significantly lower than the double core (p<0.05). This suggests that inclusion of 
dextran does decrease the amount of PLL deposited onto the core surface; however, this is 
mitigated by including it in the outer core region compared to adsorbing it onto the surface. 
This conclusion is reinforced by comparing the zeta potentials after the next layer of 
polyelectrolyte (PLG) is deposited. While both dextran conditions are again lower than the 
single core, only the absolute magnitude of adsorbed dextran is significantly lower than the 
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single core (p<0.05). As such, dextran was encapsulated in the outer core for subsequent 
experiments.  
The amount of fibrinogen deposited in the last layer on the exterior of the particle 
was quantified. A total of 6.3 ± 0.2 μg/mL fibrinogen was deposited onto the PEM capsule 
surface as determined by fluorescence intensity of a PEM capsule with fluorescent 
fibrinogen deposited onto the surface (Figure 21A).1 As before, washed human platelets 
adhere to the surface of the PEM capsule to form the platelet-HyPEMs (Figure 21B) 
without inducing rupture of the PEM wall.  
 
Figure 21. Fibrinogen on the surface of PEM capsules fabricated from double cores 
enable platelet hybridization. Fibrinogen (green, Alexa Fluor 488) is localized to the 
exterior of the PEM capsule (red, PLL-RBITC) as seen in a cross section (A) and 3D 
rendering of the same in the inset. Platelets (blue, cell membrane stain) adhere to the 
PEM capsules (B), as seen in a cross section of a single platelet-HyPEM and 3D 
rendering of the same in the inset. Scale bars = 5 μm. 
While stiff substrates coated with fibrinogen have been shown to cause platelet 
activation upon binding via activation of the αIIbβ3 integrin, this suggests that PEM capsules 
are soft enough to prevent any substantial platelet activation during the hybridization 
event.160 To confirm this, hybridized platelet activation was investigated using an Annexin 
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V-Alexa Fluor 488 conjugate stain and a PAC-1-FITC conjugate stain. Annexin V is 
specific for phosphatidylserine (PS) exposure, which is associated with platelet activation, 
and PAC-1 is specific for activated integrin αIIbβ3 and is therefore a marker of platelet 
activation.69,160 Platelets hybridized onto PEM capsules (Figure 22A) were compared to 
platelets adhered onto fibrinogen coated glass beads (diameter = 3 µm) as a positive control 
(Figure 22B) as they represent a substantially stiffer substrate than the PEM capsules. 
Annexin V intensity was normalized to platelet intensity (Figure 22C), which shows 
statistically significant lower PS exposure on platelets hybridized to PEM capsules 
compared to platelets adhered onto fibrinogen coated glass beads (0.29 ± 0.03 and 0.35 ± 
0.01, respectively).1  
 
Figure 22. Hybridized platelets remain quiescent due to the softness of PEM capsules. 
Activation of platelets (indicated by arrows in inset) hybridized to PEM capsules (red, 
PLL-RBITC) (A,D) or fibrinogen coated glass beads (B,E) was quantified using 
phosphatidylserine exposure (green, Annexin V-Alexa Fluor 488) (A-C) or PAC-1 
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(green, FTIC) (D-F). Results are represented by the mean ± SD, n = 3-4. Statistical 
significance: * p<0.05. Scale bars = 20 μm. 
Similarly, PAC-1 intensity was normalized to platelet intensity to quantify platelet 
activation (Figure 22F), which shows that activation of αIIbβ3 integrin is two orders of 
magnitude less when platelets are adhered onto PEM capsules (0.0005 ± 0.0003) compared 
to the fibrinogen coated glass beads (0.06 ± 0.02).1 These results confirm that the PEM 
capsules are biochemically suited to enable platelet adhesion to surface fibrinogen and 
mechanically tuned (by leveraging the mechanosensing ability of platelets) to mitigate 
fibrinogen-induced activation. 
4.3.3 “Burst” Release of an Encapsulated Cargo 
While it is ideal that hybridized platelets remain quiescent and do not perturb the 
morphology or structure of PEM capsules in non-target environments, it is essential that 
they rupture the PEM capsules once activated and contracting. To evaluate if the PEM 
capsules are susceptible to platelet contraction-induced rupture, the PEM capsules were 
loaded with a model payload (dextran-RBITC) and monitored while in a clot-like gel. The 
PEM capsules were mixed with fibrinogen, washed platelets, and clotting activators (2 mM 
magnesium, 10 mM calcium, and 1 U/mL thrombin) to polymerize the fibrinogen into 
fibrin and activate the platelets.  
PEM capsule rupture induced by activated, hybridized platelets and release of 
dextran-RBITC can clearly be seen in Figure 23. Both activated hybridized platelets and 
platelet aggregates are shown breaching (Figure 23A), fracturing (Figure 23B), and fully 
collapsing the PEM capsule (Figure 23C).1 This significant and severe disruption in PEM 
capsule morphology resulted in the release of the model payload, dextran-RBITC (Figure 
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23B-D and Figure 24).1 The structurally damaging effects of the force generated by 
contracting, hybridized platelets is shown in Figure 23D, where the platelet has contracted 
on top of the PEM capsule with such force that material failure of the PEM capsule 
occurred, resulting in the formation of a hole through PEM capsule wall to enable the 
“burst” release of the model payload. 
 
Figure 23. Platelet contractile force is sufficient to rupture PEM capsules in “clot-
like” gels to release a model biotherapeutic payload. PEM capsules (outer dextran-
FITC, green) with an encapsulated model payload (dextran-RBITC, red) were 
immobilized in clot-like gel consisting of fibrin (fibrinogen-AF488, green) and 
activated platelets (membrane dye, blue). Platelets adhered on the surface of PEM 
capsules are seen rupturing the capsule wall (A-D), resulting in release of the inner 
model payload (B-D). Contracting, adhered platelets are seen “popping” open a PEM 
capsule (D), enabling release of the inner model payload. Due to differences in 
intensity between dextran-FITC and fibrinogen-AF488, fibrin may be extremely faint 
in order to avoid oversaturation of the PEM capsule fluorescent channel. All scale 
bars = 10 μm.  
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It is important to note that the dextran-FITC from the outer core is retained in the 
PEM capsule, indicating the outer dextran layer is non-covalently interacting with the 
highly-charged PEM wall, inhibiting its release into the fibrin matrix despite PEM capsule 
rupture. In fact, PEM capsules without the dextran layer do not show any burst release of 
model payload during platelet contraction as seen in the initial investigations of this 
chapter, suggesting its presence in the PEM capsule formulation is necessary to facilitate a 
full, “burst” release following a rupture event.  
 
Figure 24. Platelet contractile force-mediated rupture enables “burst” delivery of the 
encapsulated model biotherapeutic in “clot-like” gels. PEM capsules (outer dextran-
FITC, green) with an encapsulated model payload (dextran-RBITC, red) were 
immobilized in a clot-like gel consisting of fibrin (fibrinogen-AF488, green) and 
activated platelets (membrane dye, blue). Platelets adhered on the surface of PEM 
capsules are seen rupturing or collapsing their capsule walls (A-J), resulting in release 
of the payload. Panels G and J represent Z-stack images of panels F and I, which show 
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release of the payload out of the interior of the PEM capsule due to nearby platelet 
contraction. Due to differences in intensity between dextran-FITC and fibrinogen-
AF488, fibrin appears faint in order to avoid oversaturation of the PEM capsule 
fluorescent channel. All scale bars = 10 μm. 
  Conclusions 
These results indicate that not only do the PEM capsules comprise the appropriate 
biochemical cues to facilitate platelet hybridization without substantial activation, they also 
possess suitable mechanical and structural properties to enable platelet contractile force-
mediated rupture of the PEM capsule followed by “burst” release of the encapsulated 
payload. These features are due to the fibrinogen on the surface of the PEM capsule as well 
as the dextran layer that separates the encapsulated model payload from non-covalently 
interacting with the highly-charged PEM wall. While the studies in this chapter utilized 
fluorescently tagged dextran as the model cargo, to more definitely determine its potential 
as a drug delivery paradigm, in vitro studies ascertaining its effects on efficacy of an 
already known biotherapeutic are required. As this paradigm utilizes the patient’s own 
platelets as the sensor and actuator of targeted delivery, using this formulation to deliver 
clot augmenting drugs to a thrombus or vascular injury site would be an appropriate 
application. Delivery of fVIII to treat bleeds in hemophilia A patients was therefore chosen 




CHAPTER 5.  PLATELET-MEDIATED TARGETED DELIVERY 
OF FACTOR VIII IN VITRO 
Results described in this chapter regarding development and characterization of the 
optimized PEM capsule have been reported in ACS Nano.1 
 Hemophilia A 
Congenital hemophilia A is a recessive X-linked genetic bleeding disorder that 
affects approximately 20,000 patients in the United States. It is caused by mutations in the 
F8 gene (~1,300 have been identified) that adversely affects the activity or production of 
the plasma protein, fVIII, for which it encodes.161,162 As this protein is necessary in the 
clotting cascade, these mutations result in an inability of the patient to form a blood clot, 
giving them a very high risk of hemorrhage after minor injury. Hemophilia A is further 
characterized by severity, which is correlated to the severity of the genetic mutation in the 
F8 gene.163 Roughly 25% of hemophilia A patients have mild hemophilia, which is 
characterized by plasma fVIII activity levels ranging from 6-30% of a healthy person. 
Plasma fVIII activity levels ranging from 1-5% is identified as moderate hemophilia (15% 
of patients), and a patient with less than 1% is considered to have severe hemophilia (60% 
of patients). 
In order to prevent or treat bleeds, there are several clinically available treatment 
options. For patients with mild hemophilia A, desmopressin is commonly used. This can 
be administered intravenously, subcutaneously, or intranasally and exhibits a half-life of 
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5-8 hours. While the mechanism is not clearly understood, it can increase fVIII activity 
level 2 to 6-fold over the patient’s baseline value.164 
Patients with moderate and severe hemophilia A typically use fVIII replacement 
therapy in which they intravenously inject either plasma-derived or recombinant fVIII, 
resulting in systemic exposure of the biotherapeutics to the patient.28,29 These are 
administered according to one of two dosing schedules depending on the severity and 
frequency of breakthrough bleeding events a patient experiences. For patients that 
experience few breakthrough bleeds (mild and moderate hemophilia), an on-demand 
schedule may be used wherein intravenous administrations only occur to treat an active 
bleeding event. Several injections may be required to abate a single bleed depending on 
severity. This dosing schedule is less expensive and generally less intrusive into the 
patient’s life if adequate. 
A prophylactic administration is used for patients with severe hemophilia or patients 
that experience several breakthrough bleeding events. Here, fVIII is administered several 
times a week as the half-life of recombinant fVIII range from approximately 8-19 hours.165 
This ensures a baseline plasma fVIII activity level is maintained in order to prevent 
breakthrough bleeding events. These patients often still experience breakthrough bleeds, 
though they are less frequent, requiring additional on-demand injections of fVIII or another 
pro-clotting biotherapeutic.166  
5.1.1 Hemophilia A with Inhibitory Antibodies 
While prophylactic administration of fVIII enables successful management of bleeds 
for the majority of severe hemophilia patients, this treatment does not work for about 30% 
of severe hemophilia patients (~3,000 to 4,000 patients in the US) because they develop 
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anti-fVIII inhibitory antibodies.30 These antibodies bind to active domains within fVIII that 
partially or fully inactive the protein. Spontaneous development of these inhibitors to 
endogenous fVIII in a patient without hemophilia A is identified as acquired hemophilia 
A. This can occur in both genders, and while the exact cause is unknown, development is 
typically associated with the presentation of another disease or condition and is not always 
permanent.167,168 These antibodies are termed autoantibodies, which bind to either the A2 
or C2 domain (but not both).169,170 Binding to the A2 domain interferes with fVIII binding 
to factor IXa, and inhibitor binding to the C2 domain interferes with fVIII binding to 
platelet phospholipid, vWF, and cleavage by factor Xa and thrombin. 
However, acquired hemophilia A is rare, and the majority of hemophilia A patients 
with inhibitory antibodies are those with congenital hemophilia A that develop them to 
exogenous replacement fVIII. These patients typically have a polyclonal response, 
developing inhibitors to both the A2 and C2 domains.170 Inhibitors developed by congenital 
hemophilia patients are termed alloantibodies and result in complete inhibition of the fVIII 
replacement therapy.169,170  
Development of inhibitors for congenital hemophilia A patients typically occurs 
within the first 150 exposures with the median development occurring between the 10th and 
15th exposure, and as such, initially affect the patient while in the pediatric stage.171 
Development of inhibitors is correlated to the type of F8 mutation responsible for the 
patient’s hemophilia.172 Thus,  risk of inhibitor development increases with a family history 
of inhibitors – 48% compared to 15% risk of development, respectively.173  
5.1.2 Clinically Available Treatment Options for Hemophilia A Patients with Inhibitors  
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The presence of inhibitors severely limits the effective treatment options for these 
patients towards abating bleeds. There are three main treatment options that are currently 
clinically available for congenital hemophilia patients, which include immune tolerance 
induction (ITI) therapy or the use of bypassing agents like activated factor VII (fVIIa) or 
activated prothrombin complex concentrate (i.e. FEIBA®).174 Patients undergoing ITI 
therapy receive regular administration of fVIII multiple times per week for a prolonged 
duration to achieve peripheral tolerance. ITI therapy has a success rate of ~70%; however, 
it is not appropriate for all patients as there are several drawbacks. The age in which a 
patient develops inhibitors, the baseline titer level, and peak titer level can preclude patients 
from ITI therapy as poor candidates to achieve tolerance. Generally, patients should be put 
on ITI therapy within two years of inhibitor development. Initiation of treatment can be 
delayed until the patient’s titer is below 10 BU/mL; however, recent investigations have 
shown some high-titer patients and those of older age can achieve tolerance.175,176 
Treatment can also make treating breakthrough bleeds problematic, as bypassing agents 
cannot be used if the inhibitor titer is greater than 10 BU/mL due to the risk of catheter-
associated thrombosis.177 Furthermore, as the treatment requires several injections per 
week over a period of several months or years, this necessitates large financial resources 
as well as time investment into the treatment.  
Use of a bypassing agent for patients that do not qualify for ITI therapy or are adverse 
to the treatment plan is an alternative though there exists shortcomings for each specific 
therapeutic option.31 Recombinant fVIIa (NovoSeven®) activates coagulation through the 
extrinsic pathway, thereby circumventing the need for fVIII replacement therapy. While 
extremely effective, it has an extremely low half-life (~1-2 hours), requiring daily 
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injections if dosing on a prophylactic schedule.34 Therefore, the clinical utility of this 
treatment falls heavily in an on-demand dosing schedule. Furthermore, NovoSeven® has 
been shown to cause thrombotic side effects in otherwise healthy patients experiencing 
hemorrhage, and while hemophilia patients are not at high risk for this side effect, it 
nonetheless remains a risk, especially if in combination with another pro-coagulant.32,33 
Activated prothrombin complex concentrates similarly bypasses the need for fVIII by 
directly supplying the activated clotting factors that depend on fVIII’s functional presence. 
While these therapies exhibit longer half-lives, the volume that must be infused is much 
larger, which requires longer infusion times and may require visits to the clinic. 
Interestingly, patients using bypassing agents prophylactically see more breakthrough 
bleeds than patients on replacement factor with the same severity, indicating its suboptimal 
efficacy.174  
Obizur® is recombinant porcine fVIII and has recently received FDA approval for 
acquired hemophilia A patients. Their phase II/III clinical trial data on 28 patients showed 
that bleeds were positively controlled (bleed abatement or substantially decreased) in all 
patients within 24 hours despite the fact that 10 of those patients exhibited some level of 
anti-porcine fVIII inhibitors.178 Furthermore, bleeds were successfully controlled in 24 out 
of the 28 patients at longer time points.  
5.1.3 Treatment Options Undergoing Development 
Two promising biotherapeutic candidates are currently undergoing clinical trials for 
haemophilia with inhibitors: emicizumab (ACE910) and Fitusiran. ACE910 is a 
recombinant bispecific antibody that mimics fVIII’s cofactor function in the clotting 
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cascade by binding to both activated factor IX and activated factor X. It has an impressive 
half-life and can be administered subcutaneously once weekly, but it does not completely 
prevent breakthrough bleeds.179 This has been problematic in their phase III trial, as 
treatment with a bypassing agent has caused several thrombotic side effects in trial patients 
and one associated death due to rectal hemorrhage.180,181 Fitusiran is a subcutaneously 
administered biotherapeutic that can be administered once a month. It is a RNAi that lowers 
antithrombin levels, which decreases the negative feedback loop in the coagulation 
cascade, thereby promoting coagulation. No thrombotic side effects have been reported in 
their phase I clinical trial for hemophilia with inhibitors, but breakthrough bleeds have been 
reported that can successfully be manged with bypassing agents without thrombotic side 
effects.182 56% of the patients in the cohort were bleed free while 69% did not experience 
spontaneous bleeding events. 
Recently, research on PEGylating fVIII183,184 or formulating fVIII with 
nanoparticles185,186 in order to mitigate inhibitor interactions has been reported. However, 
neither strategy is ideal, as PEGylation has been shown to only prevent some inhibitor 
species from binding to fVIII184 while association with nanoparticles limits the 
bioavailability of the fVIII dose. PEGylated fVIII (Adynovate®) did receive FDA approval 
due to the longer exhibited half-life. Interestingly, a PEGylated nanoparticle construct was 
shown to adversely increase inhibitor titer in a hemophilia mouse model, which could 
possibly be due to the suggested immunogenic properties of PEG.187,188 We propose that 
the herein reported platelet-HyPEMs can shield fVIII from the patient’s inhibitors and 





PLL hydrobromide (30-70 kDa), PLG sodium salt (50-100 kDa), dextran (70 kDa), MES, 
NaCl, EDTA, sodium bicarbonate, calcium chloride, magnesium chloride, sodium 
carbonate, and human coagulation fVIII concentrate were purchased from Sigma-Aldrich 
(St. Louis, MO). PBS, collagen type 1, rhodamine B isothiocyanate (RBITC), Alexa Fluor 
488 Protein Labeling kit, CD41a-APC, and 3.2% buffered sodium citrate blood collection 
tube, were purchased from Fisher Scientific (Pittsburgh, PA). Float-A-Lyzer G2 dialysis 
tubes (MWCO 100 kDa) were purchased from Spectrum Labs. Tissue factor (TF) and 
activated factor VII (fVIIa) was purchased from Haematologic Technologies (Essex 
Junction, VT). ADVATE (antihemophilia factor (recombinant), Shire) and mAb 2-76 were 
provided by Dr. Shannon Meeks. The mAb 59D8 was kindly provided by Dr. Shawn Jobe’s 
lab at the Blood Center of Wisconsin. Chromogenix Coamatic factor VIII Assay Kit was 
purchased from Diapharma (West Chester, Ohio). PDMS (Sylgard 184) was purchased 
from Ellsworth Adhesive Systems (Germantown, WI). 3M silicone adhesive transfer tape 
(50 μm thickness) was purchased from APDMRO (Ontario, CA).  
5.2.2 Whole Blood (WB) and Platelet Poor Plasma (PPP)  
Human blood was drawn according to IRB-approved protocols per the Declaration 
of Helsinki into 3.2% sodium citrate for WB and PPP isolations. To obtain PPP, WB was 
spun down to separate platelet rich plasma (PRP) from red blood cells and the buffy coat. 
PRP was spun down a second time to separate and isolate PPP from platelets.  
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5.2.3 Loading PEM Capsules with fVIII 
To load PEM capsules with fVIII via inclusion into the calcium carbonate core, 5 
mg of fVIII from human plasma concentrate was added to 7 mL 0.33 M calcium chloride 
solution before addition of 7 mL 0.33 M sodium carbonate. Core fabrication and removal 
proceeded as previously described. To load fVIII into the PEM capsules after their 
fabrication via diffusion, 50 µg/mL of fVIII was incubated with the PEM capsules at a 
particle density of 1 million/mL for 1 hour in pH 6.25 MES buffer (137 mM ionic strength). 
The microcapsules were then washed and pelleted several times with pH 6.25 MES buffer 
(5 mM ionic strength) (400 x g for 10 minutes, no acceleration or brake) to remove any 
unloaded fVIII. 
5.2.4 Protein Labeling 
To a solution of 10 mg/mL fVIII from plasma concentrate in sodium bicarbonate 
buffer (pH 9), 150 µL of a 10 mg/mL solution of RBITC in DMF was added. The solution 
was stirred for 1 h at room temperature in the dark. To purify, the solution was either 
dialyzed against PBS (100 kDa MWCO) or run through a Bio-Rad BioGel P-30 
purification column. PLL was labeled in the same manner, but purified via dialysis (10 kDa 
MWCO) in the dark. Monoclonal antibody 59D8 was labeled and purified with AF488 
using an Alexa Fluor 488 Protein Labeling Kit. A degree of labeling between 5 and 7 was 
typically achieved.  
5.2.5 fVIII Diffusive Release 
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  Experiments measuring the diffusive release of fVIII-RBITC out of capsules were 
conducted in PPP at 37 °C and under 40 rpm agitation. At time = 0, 100 uL of each sample 
was removed and incubated in 10 mM HCl for 30 minutes to dissolve the PEM capsules, 
allowing for quantitation of fVIII loading. At appropriate time points, PEM capsules were 
pelleted and an aliquot of the supernatant was removed to measure diffusive release of 
fVIII-RBITC. A PPP aliquot of the same volume was added back to the PEM capsule 
solution to preserve sample volume. Fluorescence intensity of the supernatant was 
measured and compared to a standard curve to calculate concentration of released fVIII-
RBITC in the supernatant and then compared to the t=0 concentration to calculate the 
percent of fVIII diffusion out of the PEM capsule. All fluorescent measurements were 
taken on a Cytation 5 Imaging Reader by BioTek (Winooski, VT) and were conducted in 
triplicate. 
5.2.6 fVIII Activity in PPP 
The activity of stock fVIII (ADVATE) and fVIII (ADVATE) loaded PEM capsules 
(via supernatant during the fVIII loading procedure) was first determined with the 
Chromogenix Coamatic Factor VIII Assay Kit. An amount of 2 U/mL of fVIII was then 
added to PPP with 0.92 mg/mL mAb 2-76. Samples were incubated at 37 °C and under 40 
rpm agitation for six hours. FVIII plasma activity was determined with the Chromogenix 
Coamatic Factor VIII Assay Kit at every hour.  
5.2.7 In Vitro Microfluidic Vascular Injury Model  
Fabrication of the microfluidic followed a previously reported method with 
modifications (Figure 25).1 To form the perpendicular collagen/TF patch in the center of 
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the microfluidic channel, a PDMS-based straight channel with a width of 2 mm was 
vacuum-bonded to a clean glass slide. Collagen (0.5 mg/mL) and TF (4 nM) in 10 mM 
acetic acid was perfused through the channel and incubated at room temperature for 1.5 
hours. The PDMS straight-channel was removed and slide was rinsed with DI water and 
dried with nitrogen. A straight channel was cut into 3M silicone transfer adhesive at a width 
of 1.2 mm with a Silhouette CAMEO craft cutter (Lindon, Utah). One side of the adhesive 
was then adhered to a piece of clean PDMS. Holes were punched for channel inlets and 
outlets. The remaining side was then adhered to the glass slide containing the collagen/TF 
strip. The adhesive was aligned such that the collagen/TF strip was perpendicular to and in 
the middle of the adhesive straight channel. After adherence to the coverslip, the glass was 
blocked with 5% BSA for 1 hour. 
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Figure 25. Schematic of protocol for in vitro microfluidic vascular injury model. 
WB was perfused at 5 μL/min for 10 minutes followed by PPP at 5 μL/min for 30 
minutes (healthy sample) or 50 minutes (fVIII-inhibited samples) using a Harvard 
Apparatus Elite Syringe Pump (Holliston, Massacheusetts). Both WB and PPP was 
recalcified to 5 mM Ca and contained 2 mM Mg, CD41a-APC, 59D8-AF488, 0.92 mg/mL 
mAb 2-76 inhibitory antibody for fVIII-inhibited samples, and experiment condition. All 
samples were kept at the same total volume and contained the same WB or PPP volumes.  
The collagen patch was monitored over time via confocal laser scanning 
microscopy using a Zeiss LSM 700 system (Thornwood, NY). Tile scans were taken of the 
entire patch after the experiment ended and used to measure fluorescence intensity of 
fibrin, platelets, and fVIII on the patch via Image J. 
5.2.8 In Vitro Clot Formation Time 
Citrated whole blood was mixed with 0.92 mg/mL mAb 2-76 inhibitory antibody 
for 30 minutes followed by addition of 5 mM Ca, 2 mM Mg, and 12 pM TF. Samples with 
blebbistatin were incubated with 10 µM blebbistatin for 1 hour before addition of clotting 
actiavtors. ADVATE or PEM capsules loaded with ADVATE were added at the 
appropriate concentration and incubated for an additional 10 minutes. ADVATE activity 
was confirmed immediately before addition using the Chromogenix Coamatic Factor VIII 
Assay Kit. Samples (50 uL) were loaded into wells and washed with PBS to remove soluble 
blood products at appropriate time points until the wash solution was clear. Samples were 
considered clotted when the clot covered the bottom of well and remained unchanged 
between time points.  
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5.2.9 Statistical Analysis  
All data was reported as the mean ± standard deviation of at least 3 experiments and 
calculated on GraphPad Prism 7.0 (San Diego, CA) using one-way analysis of variance 
(ANOVA) with Dunnett’s correction or student’s t test with Welch’s correction. 
 Results and Discussion 
5.3.1 Encapsulation of fVIII and Diffusive Release 
The biotherapeutic payload is contained in the inner core and was either 
encapsulated in the core during calcium carbonate core fabrication or via diffusion after 
core chelation and PEM capsule purification.26,147,149 Encapsulation efficiency of fVIII in 
calcium carbonate cores is 79.8 ± 11.3%, yielding a loading efficiency of 40.0 ± 14% after 
core removal.1 The loading efficiency of fVIII via diffusion varied with loading 
concentration; however, a loading concentration of 50 µg/mL was chosen that yielded a 
51.2 ± 2.6% loading efficiency (Figure 26).1  
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Figure 26. Characterization of fVIII loading via diffusion into the PEM capsules. The 
encapsulated concentration and encapsulation efficiency was characterized for 
various loading concentrations of fVIII (A). A confocal micrograph cross section (B) 
shows encapsulated fVIII (fVIII-RBITC, red) is completely distributed throughout 
the PEM capsule interior. Results are represented by the mean ± SD. Scale bar = 10 
µm.  
PEM capsules have been reported in the literature to be porous depending on the 
chemical characteristics of polyelectrolytes used, number of PEMs deposited, and medium 
in which they are dispersed (i.e. pH and ionic strength).189,190 The porosity and its effects 
on fVIII diffusion out of the PEM capsule during circulation in blood are of particular 
concern. To investigate the extent of diffusion, PEM capsules were loaded with fVIII 
tagged with RBITC (encapsulated during calcium carbonate core formation) and incubated 
in platelet poor plasma (PPP) at 37 °C for 1 week to simulate circulation in non-target, 
healthy vascular environments. Fluorescence of the supernatant was measured at specific 
time points and compared to a standard curve to determine the amount of diffused fVIII. 
PEM capsule formulations with and without dextran in the outer core region were 
investigated to ensure the dextran layer did not adversely affect the porosity of the PEM 
capsule. Both formulations show the same trend, with 56 ± 2% and 48 ± 3% of fVIII 
diffusing out of PEM capsules with and without dextran, respectively, after 6 hours 
incubation (Figure 27A).1 Within 24 hours, 70 ± 1% and 69 ± 2% of fVIII diffuses out of 
the PEM capsules, which plateaus to just below 80% for both formulations after 2 days 
incubation (Figure 27B). Ideally, all of the encapsulated fVIII would be retained in the 
PEM capsules during circulation for this type of delivery system; however, because the 
delivery system is designed to quickly abate bleeding, the PEM capsules should target and 
deliver fVIII within the first few hours after administration. Approximately 70% fVIII is 
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retained in the PEM capsules after the first two hours, enabling it to be a viable system 
under clinically relevant time frames to treat bleeding complications in hemophilia 
patients.  
 
Figure 27. Characterization of fVIII diffusion. PEM capsules were incubated in 
platelet poor plasma (PPP) for 1 week at 37ºC to simulate circulation in non-target 
areas. The extent of fVIII diffusion out of the PEM capsules during the initial 6 h (A) 
and 1 week (B) of incubation are shown. Results are represented by the mean ± SD, 
n=3. 
To further verify the applicability in clinically relevant time frames, we monitored 
the activity of free fVIII in PPP containing a potent fVIII inhibitory antibody (mAb 2-76)191 
to mimic acquired hemophilia. PEM capsules loaded with fVIII or fVIII delivered 
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systemically were added to PPP samples at 2 U/mL and incubated at 37 °C. The activity of 
free fVIII in the plasma was measured every hour over a six hour period with a two-stage 
chromogenic assay and normalized to the initial fVIII activity level of each sample (Figure 
28A).1  
 
Figure 28. Characterization of fVIII activity in platelet poor plasma (PPP). Factor 
VIII loaded PEM capsules or free fVIII were incubated in PPP in the presence of 
inhibitory antibodies at 37 ºC for 6 hours. The activity of fVIII in the plasma was 
determined using a two-stage chromogenic assay at one hour intervals. Activity 
normalized to initial activity (A) and absolute activity (B) are shown. Results are 
represented by the mean ± SD, n = 3-6 experiments. Statistical significance: * p<0.05, 
** p<0.01, and *** p<0.001. 
While the activity of systemically delivered fVIII gradually decreases over time, the 
activity of fVIII delivered via PEM capsules significantly increases in the first two hours 
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compared to the initial activity. This is likely due to the fact that fVIII measured by the 
activity assay in the PEM capsule samples is fVIII that has diffused out of the PEM 
capsules. Thus, the recently diffused fVIII experiences a brief period between its diffusion 
and binding with an inhibitory antibody in which it retains activity. This is further 
supported by comparing the absolute activity values of fVIII delivered via PEM capsules 
and systemic exposure (Figure 28B).1 While the activity of free fVIII is significantly higher 
at t = 0 hours for systemic delivery, the activity of fVIII in the plasma from the PEM 
capsule samples is significantly higher at t = 2 hours. While the full dose of fVIII is 
immediately exposed in the systemic case, only 30% of encapsulated fVIII has been 
diffused through the PEM capsule at t = 2 hours. Its higher activity at t = 2 hours despite 
the lower concentration of free fVIII suggests some of the diffused fVIII has yet to interact 
with inhibitory antibodies at the time the activity assay was conducted. While diffusion is 
not the primary mode of delivery for this platelet-contraction mediate delivery mechanism, 
the fact that the fVIII plasma activity at t = 2 hours is higher at only 30% of the dosage 
relative to systemically delivered fVIII further demonstrates the clinical utility of fVIII 
loaded PEM capsules for patients with inhibitors in the context of on-demand time frames 
to treat breakthrough bleeds. 
5.3.2 FVIII-Loaded HyPEMs Result in Increased Fibrin Production Compared to 
Systemic fVIII in a Microfluidic Vascular Injury Model Using fVIII-Inhibited Blood  
Efficacy of the system was first evaluated by assessing the extent of fibrin formation 
(the final product of the coagulation cascade) utilizing a microfluidic vasculature model 
previously reported in the literature with several modifications.192 The microfluidic device 
contains a collagen/tissue factor patch in the middle of the channel to enable a defined 
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region for coagulation for image quantitation. First, a vacuum-bound microfluidic was used 
in the reported device to both print the collagen/tissue factor patch as well as to form the 
perpendicular channels during sample perfusion over the patch. For simplicity, an 
adhesive-bound microfluidic was used in this work to form the perpendicular channels 
during sample perfusion. Second, the reported device used 4 g/mL corn trypsin inhibitor 
(CTI) as the sole anticoagulant and perfused whole blood through the 20 minute 
experiment. The use of CTI was attempted in this work, which occasionally worked (Figure 
29A); however, it resulted in passive platelet aggregation in the tubing, which perfused into 
the channel causing massive artificial aggregation on the patch, and in several cases, caused 
the forming clot to rip off of the patch (Figure 29B,C). Varying CTI concentrations (4 and 
8 g/mL), calcium concentrations (5, 8, and 10 mM), shear rates (100, 500, and 1,000 s-1), 
and perfusion durations (10, 15, and 20 minutes) were tried in the presence of CTI, seldom 
with positive outcomes (i.e. coagulation without artificial platelet aggregation). CTI in the 
presence of citrate and heparin reversed by protamine sulfate were tried as alternative 
anticoagulants, but yielded results similar to CTI alone or did not enable fibrin formation. 
As such, citrated whole blood (recalcified) was perfused over the patch for 10 minutes in 
order for platelets to sufficiently adhere to the patch. This was followed by perfusion of 
citrated PPP (recalcified) to enable fibrin formation. Removing platelets effectively 




Figure 29. Confocal micrographs of the left side of the collagen and tissue factor patch 
show inconsistent fibrin and platelet formation during perfusion of whole blood 
utilizing corn trypsin inhibitor as the anticoagulant. Images were taken during 
perfusion wherein (A) normal platelet aggregation and fibrin formation was 
occasionally seen on the patch area. However, the majority of the time platelet 
aggregates perfusing out of the tube (B) ripped the forming clot off of the patch or 
(C) adhered onto the patch resulting in an inaccurate increase in platelet aggregation 
and fibrin formation. Platelets were stained with CD41a-APC (blue), fibrin with 
59D8-AF488 (green), and fVIII loaded PEM capsules with fVIII-RBITC (red).  
This optimized device enables fluorescence-based quantitation of platelet adherence 
to and fibrin formation on a patch of collagen and tissue factor printed in the middle of the 
microfluidic channel (Figure 30A).1 Healthy patient samples were used to investigate the 
effects that different components of the PEM capsule formulation had on efficacy. It was 
hypothesized that the dextran layer was required for “burst” release of fVIII, fibrinogen 
was required for platelet hybridization and patch targeting, and fVIII was required for 
efficacy. PEM capsules were loaded with fVIII via encapsulation into the calcium 
carbonate core. Fibrin intensity on the patch (determined using the fibrin-specific antibody, 
mAb 59D8-AF488)193  normalized to patch area and platelet density was used as a 
downstream indicator of fVIII efficacy (Figure 30B).1  
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Figure 30. Microfluidic vascular injury model using healthy samples show fVIII 
loaded platelet-HyPEM result in increased fibrin formation. (A) A schematic of the 
microfluidic showing cross sectional (top) and top-down (bottom) perspectives with 
the collagen/tissue factor patch in the middle of the channel in purple shown. 
Quantitative analysis was performed by normalizing fibrin intensity to platelet 
intensity and patch area (B). Tiled confocal micrographs of the patch are shown for 
the healthy control condition (C), 0.05 U/mL systemic fVIII (D), and 0.01 U/mL fVIII 
loaded platelet-HyPEMs: in the full formulation (E), without dextran (F), without 
fibrinogen (G), and without fVIII (0 U/mL fVIII) (H). Fibrin, platelets, fVIII loaded 
platelet-HyPEMs, and empty platelet-HyPEMs were labeled with mAb 59D8-AF488 
(green), CD41a-APC (blue), fVIII-RBITC (red), and PLL-RBITC (red), respectively. 
Results are represented by the mean ± SD, n = 3-4. Statistical significance: **p<0.01 
and ***p<0.001 compared to 0.01 U/mL fVIII loaded platelet-HyPEM. A total of 8 
donors were used. Scale bar = 200 μm. 
Both the healthy control (Figure 30C) and systemic fVIII (Figure 5D) expectedly 
result in less fibrin formation, normalized fibrin intensity of 6.3 ± 1.8 and 9.7 ± 1.0, 
respectively, compared to the full platelet-HyPEM formulation, 13.5 ± 2.0 (Figure 30E).1 
All platelet-HyPEMs missing one component of the full formulation also produce less 
fibrin than the full platelet-HyPEM formulation. Platelet-HyPEMs without dextran (Figure 
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30F), without fibrinogen (Figure 30G), and without fVIII (Figure 30H) result in a 
normalized fibrin intensity of 8.0 ± 2.2, 4.4 ± 1.9, and 8.0 ± 1.2 respectively.1 This data 
suggests that all components of the platelet-HyPEM formulation (dextran layer, fibrinogen, 
and of course loaded fVIII) are necessary for the operational drug delivery system. 
The efficacy of platelet-HyPEMs was then investigated using fVIII-inhibited blood 
by adding the fVIII inhibitory antibody (mAb 2-76)191 to the samples in order to mimic the 
conditions of hemophilia A with inhibitors. The PPP perfusion time was increased to 50 
minutes to allow sufficient fibrin formation for quantitative comparison (Figure 30A). Two 
concentrations of systemic fVIII (0.05 U/mL and 0.5 U/mL) were investigated that 
represent 5% and 50% normal plasma activity levels, respectively (Figure 30B,C). The 
normalized fibrin intensity of 0.05 U/mL systemic fVIII is 0.1 ± 0.05, which increased to 
0.5 ± 0.3 when the fVIII systemic concentration increased to 0.5 U/mL fVIII.1 When 
platelet-HyPEMs loaded with 0.01 U/mL fVIII (Figure 30D) were used, the normalized 
fibrin intensity increases to 1.9 ± 0.6, which is a 3.8x increase compared to 0.5 U/mL 
systemic fVIII.1 Notably, this significant increase occurs even though the fVIII 
concentration used in the platelet-HyPEMs was over an order of magnitude less than the 
fVIII concentration used for systemic exposure.  
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Figure 31. Microfluidic vascular injury model using fVIII-inhibited samples showed 
platelet-HyPEMs increased fibrin formation by a factor of 3.8. Quantitative analysis 
was performed by normalizing fibrin intensity to platelet intensity and patch area 
(A). Tiled confocal micrographs of the patch are shown for 0.05 U/mL systemic fVIII 
(B), 0.5 U/mL systemic fVIII (C), and 0.01 U/mL fVIII loaded platelet-HyPEMs (D). 
Fibrin, platelets, and fVIII loaded platelet-HyPEMs were labeled with mAb 59D8-
AF488 (green), CD41a-APC (blue), and fVIII-RBITC (red), respectively. Results are 
represented by the mean ± SD, n = 3. Statistical significance: *p<0.05 and **p<0.01 
compared to 0.01 U/mL fVIII loaded platelet-HyPEM. A total of 5 donors were used. 
Scale bar = 200 μm. 
 For comparison to clinically used treatments, addition of systemic fVIIa as the pro-
coagulant was investigated with fVIII-inhibited blood in the same microfluidic design. 
During the first 10 minutes wherein whole blood was perfused, significant deposition of 
single platelets as well as platelet aggregates could be seen. Fibrin formation during the 
last couple of minutes of whole blood perfusion was also witnessed. As this was not 
witnessed during whole blood perfusion for the healthy patient sample conditions, this 
indicated a substantial pro-coagulant environment, especially within the context of a 
bleeding disorder. At the end of the 10-minute perfusion, the platelets in the front (left side) 
of the patch had aggregated into one vast aggregate, such that all the platelets in that region 
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of the patch were consolidated into the aggregate to occlude the entire width of the 
microfluidic channel (1 mm) (Figure 32). While this experimental condition was the only 
conducted once, the initial in vitro results substantiate concerns of using fVIIa in the clinic 
for potential risk of thrombotic side effects. 
 
Figure 32. Microfluidic vascular injury model demonstrates the thrombotic risk of 
using activated factor VII (fVIIa) as the pro-coagulant in fVIII-inhibited blood. A 
tiled confocal image shows substantial thrombosis and microchannel occlusion seen 
after perfusion of fVIII-inhibited blood with fVIIa for 10 minutes over the collagen-
tissue factor patch. Platelets (CD41a-APC) and fibrin (59D8-AF488) are seen in blue 
and green, respectively.  
5.3.3 FVIII-Loaded HyPEMs Shortened Clot Formation Time in the Presence of fVIII 
Inhibitors Compared to Systemic fVIII 
While the microfluidic model demonstrated fVIII loaded HyPEMs increased fibrin 
formation in the presence of fVIII inhibitors compared to systemic controls, there are 
limitations correlating fibrin formation with formation of a stable clot. To that end, we 
monitored clot formation on the bulk scale using a previously reported well plate assay to 
determine the clot formation time for various conditions.194 PEM capsules were loaded 
with commercially available recombinant fVIII (ADVATE) via diffusion. Wells were 
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loaded with WB and were washed at specific time intervals, leaving insoluble blood clot 
products behind. A stable clot was considered formed when the bottom of the well was 
completely covered with insoluble blood clot products. Utilizing this method, we 
determined the clotting times of two control conditions (healthy and mAb 2-76 fVIII-
inhibited) and several conditions in the presence of mAb 2-76 fVIII inhibitor: 0.5 U/mL 
systemic fVIII, 0.25 U/mL fVIII loaded platelet-HyPEMs, 0.5 U/mL fVIII loaded platelet-
HyPEMs, and 0.5 U/mL fVIII loaded platelet-HyPEMs with 10 µM blebbistatin (Figure 
33). 
 
Figure 33. Clot formation analysis showed 0.5 U/mL fVIII loaded platelet-HyPEMs 
approached clotting time of healthy samples. Images of individual wells that were 
washed at 10-minute intervals showing progression of clot formation are shown (A). 
Average clotting times were calculated (B) for healthy control and mAb 2-76 inhibited 
conditions: control, 0.5 U/mL systemic fVIII, 0.25 U/mL fVIII loaded platelet-
HyPEMs, 0.5 U/mL fVIII loaded platelet-HyPEMs, and 0.5 U/mL fVIII loaded 
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platelet-HyPEMs in the presence of blebbistatin (bleb.). Results are represented by 
the mean ± SD of clotting times, n = 3-5. Statistical significance: *p<0.05 and 
****p<0.0001 compared to 0.5 U/mL fVIII loaded platelet-HyPEMs. A total of 6 
donors were used. 
The average clotting time of fVIII-inhibited samples with 0.5 U/mL fVIII loaded 
platelet-HyPEMs is 32 ± 4 minutes.1 This is 58 minutes faster than mAb 2-76 inhibited 
control conditions (90 ± 10 minutes) and 18 minutes faster than 0.5 U/mL systemic fVIII 
condition (50 ± 8 minutes).1 Wells loaded with 0.25 U/mL fVIII loaded platelet-HyPEMs 
only decrease clotting time slightly to 76 ± 15 minutes, indicating the higher dose of 0.5 
U/mL fVIII is necessary to overcome fVIII inhibition in static conditions.1  
To further confirm that platelet contraction is necessary for delivery of fVIII from 
the platelet-HyPEMs, 10 µM blebbistatin (a myosin inhibitor that prevents platelet 
contraction but not adhesion to fibrinogen)69 was added along with 0.5 U/mL fVIII loaded 
platelet-HyPEMs in the presence of fVIII inhibitor. Addition of blebbistatin results in a 
statistically significant increase in clotting time (48 ± 10 minutes, p<0.05) compared to the 
condition of fVIII loaded platelet-HyPEMs without blebbistatin, indicating platelet 
contraction is necessary for the full therapeutic release of fVIII.1 Furthermore, there is no 
statistically significant difference between the clotting time of 0.5 U/mL systemic fVIII 
and 0.5 U/mL fVIII loaded platelet-HyPEMs with blebbistatin, suggesting the decrease in 
clotting time compared to the mAb 2-76 control is due to the fVIII that had diffused out of 
the platelet-HyPEM during the assay, mimicking systemic exposure, and not a “burst” 
release of the full encapsulated fVIII payload. 
 Conclusions 
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In summary, I have developed PEM capsules that are biochemically, mechanically, 
and structurally tuned to enable platelet-mediated controlled delivery. Fibrinogen is 
effectively displayed on the PEM capsule exterior and enables platelet adherence and 
formation of the platelet-HyPEMs. The LbL fabrication provides a facile manner in which 
to tune the mechanical properties through the number of deposited polyelectrolyte layers, 
mitigating platelet activation upon hybridization and facilitating PEM capsule rupture upon 
activated platelet contraction. Finally, incorporating the dextran layer adapts the structural 
properties to facilitate the “burst” release of the encapsulated biotherapeutic payload, fVIII, 
after rupture. It should be noted, however, that the LbL fabrication process is very time 
consuming and requires substantial material resources, and as such, may not translate well 
to the manufacturing scale-up necessary for commercial production. Significant 
development in manufacturing process of PEM capsules is thus required to develop a 
method that imparts the same mechanical and biochemical properties of the construct while 
using less material and is automated to both reduce human labor and minimize batch-to-
batch variation. 
I have shown that platelet-HyPEMs loaded with fVIII increase fibrin formation in 
both healthy and fVIII-inhibited blood compared to systemic delivery of fVIII. 
Furthermore, fVIII loaded platelet-HyPEMs decrease clotting time for fVIII-inhibited 
samples towards the clotting time regime of a healthy patient. Our in vitro results suggest 
that platelet-HyPEMs loaded with fVIII have potential to be developed into an efficacious 
treatment method for hemophilia A patients with inhibitors because the encapsulated fVIII 
is protected from inhibitor binding, enabling a targeted “burst” release of fVIII to quickly 
rescue hemostasis. The targeted “burst” release enabled by activated platelet contractile 
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forces provides an advantage over other nanoparticle-based delivery systems for fVIII in 
the presence of inhibitors. While it was reported that adsorbing fVIII onto soy 
phosphatidylinositol (PI)-containing lipid nanoparticles decreased the ability of fVIII 
inhibitors to bind to the fVIII protein (fVIII antibody binding domains are thought to be 
protected in the lipid layer), release of full fVIII dose is reliant upon desorption of the 
protein and redistribution between the PI nanoparticles, vWF, inhibitor, and its free 
form.186 This prevents the full dose from being effectively available immediately after 
administration. Moreover, the PI-nanoparticles do not include a targeting moiety, which 
results in fVIII desorbing in non-target areas without the ability to significantly accumulate 
at a target area. In contrast, our targeted system protects the full, encapsulated fVIII protein 
from inhibitor binding during circulation and can theoretically deliver 70% of the initial 
fVIII dose upon activated platelet contraction at the injured site within 2 hours after 
administration. 
Development of a targeted drug delivery system that leverages platelet contractile 
force as the delivery mechanism represents a paradigm shift for targeted drug delivery 
systems. In this system, platelets are used as “smart micromachines” enabling sensing of 
the target site when exposed to soluble platelet activators and then delivery upon 
mechanical contraction. This is a more active approach to targeted drug delivery because 
it enables immediate delivery of high, localized dosages to quickly augment hemostasis, 
especially when compared to other targeted systems that rely on diffusive release, chemical 
or enzymatic dissolution, or the use of external equipment (i.e. lasers or magnets). While 
this was a clearly useful drug delivery system for fVIII in the presence of inhibitors, we 
believe this can further be applied to deliver other pro-clotting agents, thrombolytics, 
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oncolytic agents, and therapies to combat infection as platelets are involved in mediating 
thrombosis, cancer, and immunity as well.   
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CHAPTER 6.  FUTURE WORK 
 Scalable Manufacturing Method for PEM capsules 
While the LbL self-assembly fabrication method for PEM capsules enables 
substantial tunability on the mechanical, biochemical, and architectural properties, it does 
not lend itself well to large-scale manufacturing because it is extremely time intensive, 
requires a large amount of excess materials, and the human involvement for every step 
imparts the opportunity for substantial batch-to-batch variability. Therefore, development 
of a scalable manufacturing method is critical in for the translational potential of this 
technology into the clinic in terms of the feasibility as a potential acquisition for a large 
pharmaceutical company and meeting stringent design and quality guidelines for the FDA. 
Microfluidics offer a promising strategy to fabricate microcapsules with high fidelity 
and yield. For this sub-milestone, we will develop a microfluidics-based reactor to provide 
a scalable manufacturing process that yields homogenous PEM microcapsules. The chip 
will consist of reactors for each layer deposition and will be connected with microfluidic 
channels that separate the microcapsules from polyelectrolyte solution in between layer 
deposition steps to prevent aggregation (Figure 34). Several devices in the literature have 
shown microfluidic channels can be constructed to separate blood cells based on size.195-
197 We plan to use these designs to purify the forming microcapsules from the 
polyelectrolyte solution between each reactor (layer deposition). 
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Figure 34. Schematic of a continuous-flow microreactor for PEM capsule fabrication. 
(A) Calcium carbonate cores are perfused into the microreactors where the 
polyelectrolyte layer is deposited. (B) The particles then continue to perfuse into the 
separation microfluidic to replace the polyelectrolyte solution with fresh buffer. This 
is repeated in a continuous fashion until the desired number of layers have been 
deposited. 
The flow rates, calcium carbonate core concentration, and polyelectrolyte 
concentrations will be optimized to yield microcapsules that exhibit properties similar to 
those fabricated via LbL deposition. Of particular concern is the amount of fibrinogen 
deposited onto the microcapsule and thickness of the polyelectrolyte wall as these 
biochemical and physical parameters directly affect platelet adhesion onto the 
microcapsule and their ability to rupture the microcapsule wall once activated and 
contracting. To investigate the amount of deposited fibrinogen, we will use fluorescent 
fibrinogen and determine the fluorescence intensity of the PEM microcapsule solution after 
fabrication. To determine polyelectrolyte wall thickness, we will use fluorescent poly-l-
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lysine and measure wall thickness using a super resolution confocal microscope. SEM and 
AFM will be used as additional methods to super resolution confocal microscopy to 
measure wall thickness.  
A potential pitfall for this strategy is if the calcium carbonate core or forming 
microcapsules adhere to the reactor or microfluidic channels during flow and fabrication 
due to their substantial charge. Not only would this block flow in the device, but also 
aggregation will result in large PEM microcapsules that are heterogeneously formed. 
Solutions to this problem include incorporating surfactant into the PDMS channels (i.e. 
pluronic) and constructing the reactors out of materials with either minimal charge or like 
charge of the polyelectrolyte solution being deposited. 
 In Vivo Delivery of fVIII in Hemophilia A Mouse Models with Inhibitors 
Genetically engineered hemophilia mice are the gold standard animal model in 
evaluating pro-clotting drugs for hemophilia. Specifically, evaluating efficacy of pro-
clotting drugs in the tail-clip model has shown excellent correlation to performance in 
humans.198,199 Furthermore, these mice can be conditioned with repetitive exposure of fVIII 
to produce fVIII inhibitory antibodies with inhibition behavior similar to human 
antibodies.191,200,201 This model will be used to investigate safety and preliminary efficacy 
of our system in comparison to the current clinically used treatment options (i.e. heavy 
dosing of fVIII and fVIIa). These studies will be conducted in collaboration with Dr. 
Shannon Meeks at Emory University, who not only has vast experience in these models, 
but is also a leader in the fields of fVIII inhibitors and development of recombinant fVIII 
therapies. 
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The first area of investigation using the mouse model will be initial safety of the 
PEM microcapsules after intravenous administration. As the PEM microcapsules are on 
the size-scale of individual blood cells and are loaded with a pro-clotting drug, thrombotic 
side effects due to microvascular occlusion are a concern. An experimental condition 
injecting empty PEM microcapsule will first be investigated to ensure the size of the PEM 
microcapsules will not cause occlusive or thrombotic events. PEM capsules at 100,000 or 
50,000 particles/mL will be injected into the mice once weekly for 4 weeks, followed by 
an off week and a double dose injection on the 6th week. Mice will be monitored for 
physical signs of distress throughout the 6 weeks. At the end of the 6 weeks, mice will be 
sacrificed and blood will be collected (via cardiac puncture) for complete blood cell counts 
and measurement of thrombin-antithrombin complex concentration. Once it is established 
that PEM microcapsules do not cause vascular blockage, mice will be anesthetized and 
injected with fVIII-loaded PEM microcapsules. Again, safety of the construct will first be 
investigated before efficacy in any injury models. 
After safety of the microcapsules has been established, preliminary efficacy will be 
investigated using a tail-clip model. Several controls will needed to be used here to evaluate 
potential for clinical utility and superiority. These controls include: fVIIa (NovoSeven®), 
FEIBA ®, and porcine fVIII (Obizur®). After efficacious dosages have been identified, 
investigations to determine pharmacokinetics, pharmacodynamics, and full investigation 
of platelet hybridization (activation of platelets and persistence of the construct) will be 
conducted.  
A possible pitfall is if the PEM microcapsules occlude any blood vessel and result in 
thrombotic symptoms. If this occurs, we will investigate using smaller PEM microcapsules 
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in the size range of 100-500 nm. These can be easily achieved by using polystyrene cores 
instead of calcium carbonate cores to template fabrication, which can be removed in a 
similar manner as the calcium carbonate cores (organic solvents or acid treatment). 
Similarly, unilamellar liposomes decorated with fibrinogen can be investigated as an 
alternative drug-carrying vehicle as they are a common drug delivery vehicle and have 
achieved FDA approval in several drug formulations. Platelet adhesion and rupture will 
need to be confirmed for these smaller alternative architectures if this route is necessary. 
 Delivery of Thrombolytic Biotherapeutics to Treat Pulmonary Embolism 
Heart disease is a leading cause of mortality in Western countries. Therapies that 
breakup blood clots that have caused myocardial infarction, pulmonary embolism, deep 
vein thrombosis, or stroke are either small molecules (i.e. warfarin) or biotherapeutics (i.e. 
tissue plasminogen activator (tPA) or streptokinase) that are delivered systemically.11,14 
While many of the small molecules are prescribed prophylactically to prevent recurring 
thrombosis, large doses of the biotherapeutics are required immediately after a thrombotic 
event. Because of the potential hemorrhagic side effects that are associated with tPA, there 
exists a fairly restrictive time frame (3 hours for stroke and 12 hours for heart attack) in 
which it can be administered in large doses.15 Furthermore, streptokinase, which exhibits a 
longer half-life (biphasic half-life of 18 and 83 minutes compared to 5 minutes of tPA), has 
been shown to cause immunomodulatory response, limiting its clinical utility.202  
Initial in vitro experiments determining its fibrinolytic potential using static gel 
model have been conducted (Figure 35). Fibrinogen, low-melting point agar, and thrombin 
were mixed together in TRIS buffer and poured into petri dishes. The gels were incubated 
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at 37 C for 2 hours to make the fibrin-agar gel then cooled to room temperature. Holes 
were punched into the gel and loaded with PRP, 5 mM calcium, 2 mM magnesium, 12 pM 
tissue factor, and the experimental condition (PBS as a control, 500 ng/mL free tPA, and 
PEM capsules loaded with 500 ng/mL tPA via diffusion). The gels were then incubated at 
37 C overnight. The area of each well was determined via ImageJ. Fibrinolysis resulted 
in increase of the well area due to degradation of peripheral fibrin in the gel around the 
well. 
 
Figure 35. Fibrinolysis in fibrin-agar gels demonstrate fibrinolytic activity of tissue 
plasminogen activator (tPA). Wells were punched in fibrin-agar gels and loaded with 
(A) platelet rich plasma (PRP) with PBS, (B) PRP with 500 ng/mL free tPA, and (C) 
PRP with 500 ng/mL tPA loaded HyPEMs. Gels were then incubated overnight, and 
(D) the mean area of the wells was determined to evaluate the extent of tPA-induced 
fibrinolysis. 
 Significant fibrinolysis can be seen for both free tPA and tPA loaded PEM capsules, 
though there is more fibrinolysis with the free tPA condition, as evidenced by the higher 
mean well area. Despite that tPA loaded PEM capsules do not perform as well as the free 
tPA in this assay, these are motivating initial results encouraging further studies into this 
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application. While efficacy might not be as high for tPA, it may extend half-life of the 
therapeutic, decrease potential hemorrhagic side effects, and possible modulate adverse 
immune response seen in streptokinase. Further studies determining lysis time of whole 
blood clots and extent of clot lysis in microfluidic experimental setups should be 
conducted.   
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APPENDICES 
Appendix A: Primary Hemostasis 
Platelets marginate to the blood vessel wall during circulation due to their size, 
which facilitates their function as the “first responders” to an injury on the vascular wall. 
Platelets are recruited to the site of injury through several mechanisms: adhesion to the 
newly exposed sub-endothelial matrix proteins, adhesion to the platelet plug, or adhesion 
to fibrin of a nascent clot. Once a vascular injury occurs, sub-endothelial matrix proteins 
are exposed (i.e. collagen, vWF, and fibronectin), enabling platelet adhesion through 
specific glycoproteins (GP) and integrins on the platelet surface. GPIa/IIa, also known as 
integrin 21, and GPVI adhere to collagen. GPIc/IIa (51), and GPIIb/IIIa (IIb3) bind 
fibronectin while GPIIb/IIIa (IIb3) and 53 bind fibrinogen. GPIb, 53, and GPIIb/IIIa 
(IIb3) bind to vWF. Receptor binding to these proteins initiates a contact-mediated 
outside-in pathway of platelet activation by inducing a conformational change in the 
receptor. Platelets spread into irregular shapes through multiple pseudopods as a 
downstream result of this activation.   
Their activation also results in secretion of dense granules (serotonin, calcium, 
ADP, ATP, and CD63) and alpha granules (mixture of adhesive proteins, procoagulants, 
anticoagulants, anti-lytic factors, anti-heparins, and growth-promoting factors).64 The 
proteins and compounds released in these granules serve to induce vasoconstriction, 
mediate the clotting response, promote tissue healing pathways, and further recruit 
activated platelets to the injury site. Inside-out signaling can occur when platelets are 
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exposed to soluble clotting factors (i.e. ADP or thrombin, a procoagulant enzyme produced 
in the coagulation cascade), which bind to their respective receptors on the platelet 
membrane surface. The transmission of binding events through the cytoplasm results in the 
conformational change in the IIb3 integrin and subsequent platelet activation. 
Importantly, these platelets are then allowed to bind fibrinogen and vWF to their respective 
receptors, which act as ligands to adhere to adjacent platelets, thereby facilitating platelet 
aggregation at the injury site to form a platelet plug that initially functions to stem bleeding. 
During the formation of the platelet plug, the coagulation cascade begins, resulting 
in the production of thrombin to polymerize fibrinogen into fibrin, which is integral to clot 
porosity and stiffness.64 Red blood cells and platelets adhere to the forming fibrin network, 
which enhances the integrity of the clot structure. Platelets can additionally be activated 
through this binding event, as fibrin binds to the IIb3 integrin. An additional response of 
platelet activation is platelet contraction on the fibrin fibers of which they are adhered. This 
occurs when the platelet’s myosin light chain is phosphorylated, which induces a 
contractile force through the myosin heavy chain to actin filaments. This contractile force 
is transmitted from inside the cell to outside the cell and propagates through fibrin network 
because the actin filaments are attached to the IIb3 integrin, which are adhered to fibrin 
fibers in the clot. Clot contraction enhances the mechanical robustness of the clot by further 
increasing stiffness and decreasing porosity. It also brings the vascular walls closer together 
to further stem bleeding and enhance tissue regrowth and wound healing at later time 
points.   
Appendix B: The Coagulation Cascade 
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The coagulation cascade is a complex response mechanism wherein plasma 
zymogens are converted into their enzymes, towards the end result of producing thrombin 
to cleave fibrinogen and form the fibrin network within the clot structure. Several steps 
within the clotting cascade require interaction of a negatively charged phospholipid 
membrane (i.e. as seen on activated platelets or endothelial cells) and activated co-factors. 
There are traditionally two coagulation pathways which merge at the critical thrombin 
production step: the extrinsic and intrinsic pathways.  
The extrinsic pathway is initiated when damaged endothelial cells express the 
membrane glycoprotein, tissue factor, which acts as a cofactor to activated factor VII 
(fVIIa).64 Tissue factor binds fVIIa to fully expose its activation site, which enhances its 
enzymatic activity to produce more fVIIa, as well as activation of factor X and factor IX. 
Production of fXa and fIXa enables the conversion of prothrombin to thrombin. While the 
concentration of thrombin produced is not sufficient enough to maintain hemostasis due to 
the negative feedback of tissue factor pathway inhibitor (secreted by endothelial cells and 
activated platelets), it is sufficient enough to initiate the intrinsic pathway. An additional 
negative feedback loop exists for the extrinsic pathway wherein circulating antithrombin 
covalently binds to the active sites of fXa and thrombin, resulting in its deactivation and 
clearance. 
The classical intrinsic pathway begins when thrombin produced from the extrinsic 
pathway cleaves fXI to fXIa, which then activates fIX to fIXa. In addition, thrombin also 
activates the cofactors fVIII (requiring first dissociation from vWF with which it circulates) 
and fV to their activated forms, fVIIIa and fVa.64 The tenase complex is then formed when 
fVIIIa, fIXa, and calcium associate on a phospholipid surface. This complex activates fX 
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to fXa, which then associates with fVa and calcium on a phospholipid surface to form 
prothrombinase. This activated complex then converts prothrombin into thrombin, which 
cleaves the fibrinopeptides A and B off of the fibrinogen A and  chains, thus enabling 
fibrin formation through its self-assembly. Along with several additional positive feedback 
loops, thrombin cleaves fXIII to fXIIIa, which covalently crosslinks the fibrin fibers to 
enhance its stability. Thrombin also initiates negative feedback loops that block fVIII and 
fV activation through active protein C, to modulate the hemostatic response and prevent 
thrombosis.  
Fibrinolysis is another mechanism within the hemostatic response that modulates 
clot formation to avoid pathologic clotting.64 Tissue plasminogen activator (tPA) and 
urokinase-type plasminogen activator are enzymes that cleave the zymogen plasminogen 
into plasmin, which then activates matrix metalloproteins that dissolve the fibrin network. 
Both tPA and plasminogen have a binding affinity to fibrin, resulting in enhanced plasmin 
generation. Of course, there exist fibrinolysis inhibitors that function to prevent the 
cleavage of plasminogen into plasmin (plasminogen activator inhibitors 1 and 2), decrease 
the binding affinity of plasminogen and tPA to fibrin (thrombin-activatable fibrinolysis 
inhibitor (TAFI)), and inhibit unbound plasmin directly (2-antiplasmin). 
The contact pathway also plays a role in activation of the intrinsic pathway, although 
it is believed to be a relatively minor role for in vivo hemostatic response.64 Interestingly, 
in vitro behavior of this pathway is drastically different, progressing through a slightly 
different pathway (relying on fXII) and resulting in a major activation response in 
coagulation assays compared to in vivo behavior. In vivo, the contact activation pathway 
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occurs when high molecular weight kininogen binds to cell-surface receptors, enabling 
association of prekallikrein and fXI. Cell-surface proteases then activate prekallikrein to 
kallikrein and fXI to fXIa. While fXIIa is not required, it is believed its presence may 
enhance the activation rate.   
Appendix C: Bleeding and Clotting Disorders 
Due to the integral and complex nature of both platelet function within clot 
formation and the coagulation cascade, genetic mutations affecting coagulation proteins or 
platelet function can have devastating effects that can result in life-threatening bleeding or 
clotting disorders. There are several known congenital diseases that result in dysfunctions 
in platelet function. Bernard-Soulier Syndrome occurs when platelets have defects in GPIb, 
causing interference in platelet binding to vWF, which results in prolonged bleeding 
times.64 Glanzmann thrombathenia is characterized by dysfunctional or absent GPIIb/IIIa 
on platelets, severely affecting platelet aggregation and contraction. When transmembrane 
migration of phospholipids is defective, it is called Scott Syndrome and substantially 
decreases the ability for the tenase and prothrombinase components to assemble in the 
coagulation cascade. Wiscott-Aldrich syndrome occurs when defects in actin cytoskeleton 
exists, interfering with platelet’s ability to form pseudopodia after adhering onto a 
substrate.  
Several coagulation disorders exist due to congenital mutations in genes that encode 
for hemostatic proteins.64 These include fXI deficiency, fX deficiency, fVII deficiency, fV 
deficiency, and prothrombin deficiency and all result in bleeding tendencies of varying 
severity. Infusion of donor plasma is typically the first option in treating severe bleeds for 
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these patients. Of particular note are fVIII, fIX, and von Willebrand deficiencies, which 
cause hemophilia A, hemophilia B, and von Willebrand disease, respectively. Infusion of 
plasma-derived or recombinant replacement factor is the standard of care for these patients; 
however, if the patient has developed inhibitory antibodies to the replacement factor, the 
treatment regime can become substantially more complicated and intense. On the opposite 
end of the spectrum, there are several congenital thrombophilias like antithrombin 
deficiency, protein C deficiency, and protein S deficiency that results in higher risks of 
venous thrombosis, which can cause myocardial infarction or stroke. If patients presenting 
signs of heart attack or stroke are diagnosed within a required time frame, they are 
intravenously administered a bolus dose of an antithrombotic (i.e. recombinant tPA) and 
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